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 Small GTPases of the Rho family are well established regulators of critical cellular 
functions including cytoskeletal remodeling, motility, vesicle trafficking and cell cycle control.  
Additionally, aberrant signaling and/or regulation of Rho proteins have been implicated in 
various human pathologies.  For these reasons, there is increasing interest in Rho GTPases as 
targets for therapeutic intervention.  In the current study, we aim to understand Rho GTPase 
involvement in neuronal degeneration associated with clinical cisplatin use.  Using a mouse 
model of cisplatin-induced peripheral neuropathy (CIPN) and a primary neuronal culture system 
we investigated how RhoA pathway suppression concomitant with cisplatin could prevent 
neuronal damage.  Additionally, in order to fill a large gap in the field of Rho GTPase study and 
to allow us to further understand Rho GTPase cross regulation, we sought to identify and 
characterize  novel small-molecule inhibitors of the Rho family member Cdc42. 
 Using our CIPN mouse model, we examined RhoA pathway suppression with LM11A-
31, a p75 neurotrophin receptor ligand mimetic, on both RhoA signaling and neuronal damage 
associated with cisplatin application.  We determined that cisplatin-induced decreases in 
peripheral nerve sensitivity and abnormal peripheral nerve morphologies could be prevented 
with concurrent use of LM11A-31 and cisplatin.  Additionally, cisplatin-induced increases in 
RhoA activity and expression could be inhibited by LM11A-31.  Furthermore, in vivo and in 
  
vitro studies demonstrate that cisplatin can also reduce SHP2 phosphorylation, which in turn, can 
be alleviated by LM11A-31.  These studies demonstrate the importance of RhoA signaling in the 
development of CIPN and highlight its usefulness as a potential therapeutic target. 
            To discover potential specific Cdc42 inhibitors, we applied high-throughput screening to 
identify compounds that are able to target the interaction between Cdc42 and its specific guanine 
nucleotide exchange factor, intersectin. ZCL278 was found to inhibit Cdc42 activity, expression, 
and directly bind to Cdc42.  Additionally, ZCL278 inhibits Cdc42-mediated microspike 
formation, and disrupts GM130-docked Golgi structures. ZCL278 also suppresses Cdc42-
mediated neuronal branching as well as cell motility and migration without disrupting cell 
viability. Therefore, ZCL278 is a novel small-molecule modulator of Cdc42 that will open the 
door to further study of Cdc42-mediated signaling pathways. 
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CHAPTER I:  INTRODUCTION 
 
A. The Rho Family of Small GTPases 
 
 Rho GTPases comprise a family of small GTPases (α subunits of G-proteins) within the 
larger Ras superfamily.  RhoA, the first member of this subfamily, was identified in 1985 in an 
effort to identify Ras-related genes in Aplysia (Madaule and Axel, 1985).  Since that time, at 
least 20 different proteins that belong to this family have been discovered (as reviewed by Vega 
and Ridley, 2008).  Rho GTPases are present in all eukaryotic cells, typically small in size (20-
30 kDa) and perform regulatory functions due to their intrinsic GTPase activity (as reviewed by 
Ellenbroek and Collard, 2007; Etienne-Manneville and Hall, 2002).  Acting as a molecular 
switch, Rho GTPases cycle between an active GTP-bound state and an inactive GDP-bound 
state.  Once bound by GTP, specific downstream effector proteins can transduce extracellular 
signals through a wide variety of membrane receptors including integrins, ion channels, G-
protein coupled receptors, or growth factor receptors.  Such signaling result in changes in a 
variety of cellular processes such as gene transcription, cell morphogenesis, vesicular trafficking, 
migration, and cell cycle control (as reviewed by Jaffe and Hall, 2005; Ellenbroek and Collard, 
2007; Lu et al., 2009).  
 The activity of small GTPases is tightly controlled by both positive and negative 
regulators specific for each GTPase (Fig. 1.1).  Guanine nucleotide exchange factors (GEFs) 
facilitate the exchange of GDP for GTP, thus activating the protein and allowing it to bind to 
effector molecules (as reviewed by Bustelo et al., 2007). To date, two families of GEFs 
(including over 70 total members) have been identified that activate Rho GTPases; these possess 
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either a Dbl-homology domain (DH) or a Dock Homology Region domain (DHR) (as reviewed 
by Cherfils and Zeghouf, 2013).  On the other hand, GTPase-activating proteins (GAPs) 
maintain a basal level of protein activity by catalyzing GTP hydrolysis and returning the GTPase 
to its GDP-bound (inactive) conformation through a RhoGAP catalytic domain (as reviewed by 
Cherfils and Zeghouf, 2013; Lu et al., 2009; Ridley, 2006).  Finally, guanine nucleotide 
dissociation inhibitors (GDIs) prevent GTPase cycling by either binding to the GTP-bound form 
and preventing hydrolysis or to the GDP-bound form thereby preventing activation by GEFs.  
Additionally, GDIs are also able to sequester Rho proteins in the cytosol by binding to the post-
translationally added C-terminal isoprenyl lipids (geranylgeranyl or farnesyl) of the Rho GTPase, 
which are responsible for membrane anchoring (as reviewed by Cherfils and Zeghouf, 2013; 
Dransart et al., 2005). Due to the host of functions of Rho proteins and their presence in various 
cell types, their activation likely depends on a balance between the actions of the three types of 
regulators at specific cell sites (as reviewed by Ellenbroek and Collard, 2007).  
 Our current understanding of the biological functions of the most highly conserved Rho 
GTPase family members: RhoA, Rac1 and Cdc42, has been supported by several methods 
including the use of constitutively active (CA) and dominant negative (DN) Rho GTPase 
mutants.  Early studies by Paterson et al. (1990) and Nobes and Hall (1995) in Swiss 3T3 
fibroblasts revealed the critical importance of these proteins to cell morphology, an actin-
mediated function.  Those studies showed that constitutive activation of RhoA, Rac1, and Cdc42 
resulted in the formation of stress fibers, lamellipodia, and filopodia, respectively (Fig. 1.2).  
Actin stress fibers consist of long actin filament bundles that extend across the cell and are linked 
to the extracellular matrix (as reviewed by Hall, 1998).  Lamellipodia and filopodia/microspikes, 
on the other hand, are found in motile cells as either an actin meshwork at the leading edge or 
 3 
 
protrusions of actin filament bundles from the cell surface, respectively (as reviewed by Ladwein 
et al., 2008).  Importantly, the generation of several specific Rho GTPase knock-out (KO) mice 
has greatly contributed to our knowledge of the functions of these proteins in vivo.  Both Rac-1 
and Cdc42 knockout mice do not survive birth and demonstrate defective germ-layer formation 
and gross brain abnormalities, respectively (Sugihara et al., 1998; Garvalov et al., 2007).  These 
models have illuminated crucial roles of Rho proteins in embryonic development and solidified 
their importance for cell migration and neuronal development. 
   
B.  RhoA    
 RhoA, a ubiquitously expressed member of the RhoA subfamily of Rho proteins, which 
also includes the highly homologous RhoB and RhoC, was the first described and is the most 
characterized.  Primarily a cytosolic protein, RhoA interacts with a variety of downstream 
effectors including ROCK, PIP-5, citron, PKN, and rhotekin (Fig.1.3; Michaelson et al., 2001).  
The most prominent and understood targets of RhoA signaling include the serine/threonine 
kinases Rho-associated coiled-coil containing protein kinases I and II (ROCK I, also known as 
p160ROCK or ROKβ  and ROCK II, also known as ROCKα; Matsui et al., 1996; Ishizaki et al., 
1996).  When activated,  Rho-kinases can phosphorylate a variety of substrates including myosin 
light chain (MLC) phosphatase (Amano et al., 1996; Kawano et al., 1999), LIM kinases (LIMK) 
(Amano et al., 2001; Maekawa et al., 1999) and ezrin/radixin/moesin (ERM; Matsui et al., 1998) 
which facilitate actin-myosin contractility, stress fiber formation, and interaction with the plasma 
membrane, respectively.  Additional roles of ROCK signaling include cell-cell adhesion, 
motility, and cell cycle regulation (Amano et al., 2000; Croft and Olson, 2006; Redowicz, 1999).  
Demonstrating the importance of the RhoA-Rho kinase pathway, deletion of either ROCK I or 
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ROCK II in mice is embryonic lethal and leads to a variety of pathological phenotypes including 
growth retardation, omphalocele, and open eyelids (Shimizu et al., 2005; Thumkeo et al., 2003). 
 An additional RhoA effector mDia1 (mammalian Diaphanous 1), a formin protein, is 
essential for nucleation and polarization of actin filaments (Fig. 1.3A).  The formin family of 
proteins aid in actin polymerization by binding to the barbed ends of elongating filaments, 
protecting them from capping proteins, delivering monomers to growing filaments and producing 
long, unbranched,  actin filaments (Evangelista et al., 2003; Goode and Eck, 2007; Zigmond, 
2004).  Additionally, mDia1 can bind microtubules through its association with microtubule end 
capping protein EB1/APC and promote stabilization (Wen et al., 2004).  Due to its influence on 
both actin filament nucleation and microtubule stabilization RhoA is, therefore, able to 
coordinate and modulate cytoskeletal rearrangements to facilitate stress fiber formation in 
migrating cells. 
 Currently, our understanding of RhoA signaling has been significantly aided by the 
discovery, development and utilization of activators and inhibitors (Table 1.1). For instance, the 
soluble serum factor lysophosphatidic acid (LPA), one of the earliest described activators of 
RhoA (Ridley and Hall, 1992) is a G-protein coupled receptor agonist that facilitates RhoA 
activation through the Gα12/13 subunits (Fromm et al., 1997; Gohla et al., 1998; Kranenburg et al., 
1999) and leads to gene transcription involving serum response factor (SRF) and its co-activator 
megakaryoblastic leukemia 1 (MKL1). Sphingosine-1-phosphate (S1P), another serum 
lysophospholipid, also promotes RhoA activation via the EDG receptor (EDG 3 or EDG 5) 
which also couples to Gα12/13 to regulate serum response element (SRE) mediated transcription 
(Hill et al., 1995; Buhl et al., 1995; Lee et al., 1998).  However, a major drawback of use of LPA 
or S1P lies in their lack of specificity, as both promote activity of other proteins such as Ras, c-
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Jun N-terminal kinase (JNK), extracellular-signal-regulated kinase (ERK), and phospholipase C 
(PLC) (as reviewed by Takabe et al., 2008).  Although still indirect, calpeptin has emerged as a 
more specific method to induce RhoA activation.  Through SHP2 (src homology 2 domain 
containing a non-transmembrane protein tyrosine phosphatase) tryosine phosphatase inhibition, 
calpeptin maintains negative RhoA regulator p190RhoGAP in an inactive state thus promoting 
accumulation of GTP-RhoA (Schoenwaelder et al., 2000).  
 Importantly, a variety of inhibitors have been identified that allow further dissection of 
signaling both upstream and downstream of RhoA activation (Table 1.2).  In early studies of Rho 
GTPase signaling the exoenzyme C3 transferase from Clostridium botulinum, which ADP-
ribosylates asparagine 41 in the RhoA effector binding domain, was frequently employed as a 
specific and direct inhibitor of Rho activation (Kumagai et al., 1993).  However, C3 transferase 
has poor cell permeability which results in the need for higher concentrations and longer 
incubation times, which in turn can disrupt basic cellular functions.  Since then, several indirect, 
but specific, inhibitors such as the ROCK antagonists fasudil (Nagumo et al., 2000) and Y-27632 
(Ishizaki et al., 2000; Narumiya et al., 2000) have been developed.  Both Y-27632 and fasudil 
target the ATP-dependent kinase domains of ROCK, are cell permeable, and have high affinities 
for ROCK with Ki's of 200-300 nM (Ishizaki et al., 2000; Narumiya, Ishizaki and Uehata, 2000)
 
and 330 nM (Uehata et al., 1997), respectively.  Interestingly, Evelyn et al. (2007) identified the 
small molecule CCG-1423 as a potent inhibitor of MKL/SRF-dependent transcription that is 
stimulated by Gα12/13.  Upstream of RhoA, p75 neurotrophin receptor (p75
NTR
) signaling 
facilitates the release of prenylated RhoA from Rho-GDI, thus inducing its activation (Yamashita 
and Tohyama, 2003).  LM11A-31, a p75
NTR
 ligand mimetic of the nerve growth factor (NGF) 
loop 1 in the p75
NTR
 binding domain, has recently been shown to be an inhibitor of RhoA-
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mediated signaling pathways and will be further discussed in this dissertation (James et al., 2008; 
Massa et al., 2006). 
 Aberrant RhoA activity has been implicated in a wide variety of human diseases and 
disorders. Extensive clinical and experimental studies have provided compelling evidence for the 
importance of RhoA/ROCK pathways in cardiovascular disease.  First, vasoactive agonists such 
as angiotensin II (Ang II) can activate RhoA/ROCK signaling pathways and modulate both 
contractility and vascular tone (Funakoshi et al., 2001; Guilluy et al., 2010).  Specifically, ROCK 
regulates phosphorylation of MLC, a key event in the regulation of vascular smooth muscle cell 
(VSMC) contraction, by both inhibition of MLC phosphatase (MLCP) and direct 
phosphorylation of MLC (Kimura et al., 1996).  Moreover, through MLCP inhibition, ROCK is 
able to contribute to Ca
2+  
sensitization of smooth muscle contraction (SMC)  (Amano et al., 
1996).   
 Due to these roles within VSMCs, ROCK signaling in arterial hypertension has been 
widely studied and targeted therapeutically.  Hypertension is characterized by increased arterial 
pressure resulting from increases in contractility and vascular tone as well as remodeling within 
the arterial wall.  In addition to the aforementioned roles within VSMC's, Rho kinase has been 
shown to inhibit production of the potent vasodilator, nitric oxide (NO), by negatively regulating 
endothelial nitric oxide synthase (eNOS) expression through disrupted eNOS mRNA stability 
during hypertensive states (Laufs and Liao, 1998; Takemoto et al., 2002).  Clinically and 
experimentally, RhoA/ROCK pathways have been demonstrated to be upregulated as a result of 
hypertension in human patients (Masumoto et al., 2001) and animal models (Moriki et al., 2004; 
Mukai et al., 2001).  Importantly, Uehata et al. (1997) showed that Y-27632 administration to 
renal hypertensive, deoxycorticosterone-acetate/salt treated and spontaneously hypertensive rats 
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could lower blood pressure.  Since those early studies, researchers have begun to take a more in 
depth look at events upstream of RhoA using angiotensin II-induced hypertensive rats.  Results 
showed that Y-27632 could potently promote vasodilation in hypertensive animals verses non-
hypertensive animals (Chitaley et al., 2001). Additionally, blockade of the Ang II receptor, 
receptor type 1 (AT1), could prevent RhoA/ROCK upregulation in experimental models of 
hypertension (Kataoka et al., 2002).   In humans, fasudil infusion was shown to be able to 
decrease vascular resistance and  increase forearm blood flow in hypertensive patients, further 
implicating ROCK in clinical hypertension (Kishi et al., 2005). 
 Atherosclerosis, a progressive and chronic process that is characterized by vascular wall 
inflammation and fibrosis as well as lipid and macrophage accumulation, has also been critically 
linked to ROCK activity.  First, ROCK has been implicated in the inflammatory process of 
atherosclerosis due to its ability to downregulate eNOS.  Interestingly, in a porcine IL-1β-
induced atherosclerosis model, long-term oral administration of fasudil was able to promote 
regression of coronary stenosis (Shimokawa et al., 2001). Additional work in mice with defective 
LDL-receptors that were administered a high cholesterol diet showed that Y-27632 could limit 
atherosclerotic plaque development (Mallat et al., 2003). Other mouse models of accelerated 
atherosclerosis, specifically apolipoprotein E (ApoE)-deficient mice, showed increased ROCK-
mediated smooth muscle contraction within the aorta as well as increased phosphorylation of 
ERM, a major effector of ROCK activation, in atherosclerotic plaques (Rekhter et al., 2007).  
Fasudil treatment, within ApoE-deficient mice, was able to decrease both arterial thickness and 
macrophage accumulation in atherosclerotic lesions (Wu et al., 2009).  In human patients with 
coronary artery disease (CAD), correlations between impaired endothelial cell function and 
increased ROCK activity have been documented (Nohria et al., 2006).  Oral administration of 
 8 
 
Rho kinase inhibitor fasudil in these patients resulted in significant reduction in both Rho kinase 
activity (~59%) and endothelium-dependent vasodilation, but not in healthy patients.  Such 
findings further support RhoA/ROCK signaling as a significant therapeutic target in 
cardiovascular disease, and impart more strength for their clinical use. 
 In addition to the cardiovascular system, RhoA has clearly been demonstrated to play a 
critical role in neurological problems.  RhoA is highly expressed throughout the nervous system 
and is present in both glial and neuronal cell populations (Suidan et al., 1997).  RhoA/ROCK 
signaling has been established as a negative regulator of neuritogenesis (Da Silva et al., 2003; 
Kozma et al., 1997) and synaptic plasticity (Govek et al., 2004; Van Aelst and Cline, 2004).  Due 
to these negative effects on neuronal development and stability, many studies support RhoA 
pathway inhibition to promote recovery for traumatic brain and spinal cord injury, stroke, and 
even Alzheimer's disease.  Specifically, in rats with experimental spinal cord injuries, the 
significantly increased RhoA mRNA and protein expression in neurons, astrocytes, and 
oligodendrocytes (Dubreuil et al., 2003) due to injury could be reduced by both Y-27632 and 
fasudil administration (Hara et al., 2000; Sung et al., 2003).  Although the precise role that RhoA 
plays remains elusive, we do know that during the secondary phase of neuronal injury many 
growth inhibitory signals converge on RhoA/ROCK and inhibit the regenerative ability of 
damaged neural tissue.  Some of these factors include the myelin-associated inhibitors Nogo 
(Chen et al., 2000b), myelin-associated glycoprotein (MAG; McKerracher et al., 1994) and 
oligodendrocyte-myelin glycoprotein (OMgp; Wang et al., 2002) as well as chondroitin-sulfate 
proteoglycans (CSPGs); the glial scar-associated inhibitors which are up-regulated in reactive 
astrocytes (Gopalakrishnan et al., 2008).  In addition, other studies suggest inflammatory events 
including leukocyte and endothelial T-cell migration can occur through Rho-dependent 
 9 
 
mechanisms (Etienne et al., 1998; Adamson et al., 1999) and contribute to secondary injury.  
Furthermore, work by Honing et al. (2004) demonstrated that Y-27632 treatment could prevent 
RhoA-mediated migration and adhesion of monocytes across brain endothelial cell monolayers 
(Honing et al., 2004).    
 Interestingly, previous work in our laboratory has suggested a novel role of RhoA in 
chemotherapy-induced neurotoxicity. Clinically, neuropathy associated with platinum-based 
anti-neoplastic drug use is a common, debilitating and dose limiting problem.  However, because 
neurons are not a mitotic population, cell cycle-dependent apoptotic mechanisms do not explain 
platinum-based neurotoxicity.  In vitro studies showed distinct and significant neurite retraction 
in primary cortical/hippocampal cultures treated with cisplatin (James et al., 2008).  Additionally 
in these cultures, upstream inhibition of RhoA with LM11A-31 prevented cisplatin-induced 
increases in GTP-bound RhoA and neurodegeneration.  James et al. (2010) also demonstrated 
that ROCK inhibition with Y-27632 could successfully promote recovery in a mouse model of 
cisplatin-induced peripheral neuropathy (CIPN).  A more precise role of RhoA in a CIPN model 
focusing on prevention rather than recovery, will be addressed in greater detail in Chapter II. 
 Although no specific mutations have been identified in any Rho protein in association 
with cancer, RhoA has been shown to be deregulated in leukemia, breast, lung, colon, gastric, 
bladder and testicular cancers.  Considering that the cellular functions of RhoA correspond to 
several processes required for tumor formation and progression including cell survival, 
proliferation, and regulation of migration, it is not unexpected to find aberrant Rho protein 
activity in human cancers.  Often this deregulation occurs at the level of activation or expression 
and is often due to alterations in the expression or activity of downstream effectors or other 
regulators of RhoA.   For example, the specific RhoA GEF LARG (leukemia-associated Rho 
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GEF), originally isolated from a patient with acute myeloid leukemia (AML), has been identified 
as a fusion partner of the MLL protein (mixed lineage leukemia; Kourlas et al., 2000; Reuther et 
al., 2001).  Through the MLL and LARG fusion, LARG becomes truncated upon chromosomal 
translocation which can then promote RhoA signaling pathways and leukemia development 
(Reuther et al., 2001).  Another RhoA GEF, GEFH1, has been shown to be transcriptionally 
activated by induction of mutant p53 proteins. Through this activation, GEFH1 then promotes 
accelerated tumor cell proliferation in several cancer cell lines (Mizuarai et al., 2006).  Such 
results suggest that increased RhoA activity may contribute to both invasion and metastasis, as 
well as promote growth of p53 tumors.  GAPs, such as DLC-1 and DLC-2 (deleted in lung 
cancer 1 and 2), which are known to promote GTP hydrolysis in RhoA, have been found to be 
genomically deleted in primary breast tumors (Yuan et al., 2003) or downregulated in 
hepatocellular carcinomas (Ching et al., 2003).  Reduction in RhoA-specific GAP activity would 
then lead to increased overall levels of RhoA activity.  Downstream RhoA effectors such as 
ROCK have also been demonstrated to be altered in several cancer types.  For example, ROCK 
has been demonstrated to be overexpressed in osteosarcoma (Liu et al., 2011), hepatocellular 
carcinoma (Wong et al., 2009), breast (Lane et al., 2008), testicular (Kamai et al., 2004), colon 
(Vishnubhotla et al., 2007) and bladder (Kamai et al., 2003) cancers and is highly correlated with 
increased tumor grade, progression and poor survival.   
 Thus, it is clear that proper regulation and activity of RhoA is vital to normal cellular 
function and that aberrant regulation and/or signaling to a variety of effectors can result in a wide 
array of pathology.  Importantly, abundant data support pharmacological intervention of the 
RhoA pathway as a plausible method to hinder RhoA-mediated dysfunction in both in vitro and 
in vivo models. 
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C.  Rac1 
 Rac1, a second prominent Rho protein, is ubiquitously expressed as compared to its other 
family members Rac2 and Rac3, which are predominately expressed in hematopoietic cells and 
neurons, respectively (Didsbury et al., 1989; Malosio et al., 1997).  Like RhoA, Rac1 is localized 
mainly within the cytoplasm until activation induces its translocation to the plasma membrane 
where interaction with effector proteins and induction of subsequent downstream signaling 
cascades can occur (Wennerberg and Der, 2004).  Through its primary downstream effectors 
P21-activated kinase 1 and 2 (PAK1/2), WASP family verprolin-homologous protein (WAVE) 
and to a lesser extent IQGAP, Rac1 can modulate cytoskeletal rearrangements which results in 
the formation of the motile structures known as lamellipodia or membrane ruffles as well as 
promotes cell adhesion, proliferation, and survival (Fig. 1.3B).  PAK1/2 has an N-terminal 
GTPase binding domain which, when bound by activated (GTP-bound) Rac1, relieves 
autoinhibition and enhances kinase activity (Frost et al., 1996).  PAK1/2 can then affect 
cytoskeletal organization by phosphorylating various proteins including MLCK, LIMK, 
cortactin, and components of Arp2/3 actin nucleation complex (Edwards et al., 1999; Vadlamudi 
et al., 2004).  Regulation of actin polymerization through the Arp2/3 complex also occurs via 
mDia2 (Lammers et al., 2008) and WAVE, which lacks a GTPase binding domain and requires a 
complex of Rac1 and an adaptor molecule, IRSp53, to be activated (Miki et al., 2000). The C-
terminal verprolin-homology central and acidic (VCA) motif of the WAVE/Rac1/IRSp53 
complex can then promote binding to the Arp2/3 complex and subsequent actin network 
formation (Suetsugu et al., 2006).  IQGAP, a Rac1 effector and actin-binding protein, is enriched 
at the leading edge of migrating cells (Bashour et al., 1997).  In addition to its interaction with 
actin, IQGAP also binds cytoplasmic linker protein 170 (CLIP-170) which accumulates at the 
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plus ends of growing microtubules at the polarized leading edge of lamellipodia in migrating 
cells (Fukata et al., 2002). 
 Unlike RhoA, where a multitude of activators and inhibitors are available to study related 
signaling pathways, much of our understanding of Rac1 has come from in vitro studies using 
either dominant negative (DN) or constitutively active (CA) mutant cell lines or in vivo knockout 
models.  Complete Rac1 knockout is lethal early in embryonic development (E8.5), displaying 
defective germ-layer formation and highlighting the importance of Rac1 signaling pathways in 
development (Sugihara et al., 1998).   Inducible, cell-type-specific rac1 gene knockouts have 
further expanded our knowledge and alleviated some of the limitations of DN/CA in vitro 
studies.  Some of these studies have revealed the importance of Rac1 in central nervous system 
myelin sheath formation (Thurnherr et al., 2006), in hair follicle integrity (Chrostek et al., 2006), 
and in dendritic cell antigen presentation to T-cells (Benvenuti et al., 2004).  The selection of 
Rac1 activators (Table 1.1) has been and remains limited to PDGF and EGF (Ridley et al., 1992), 
neither of which are specific nor direct stimulators of activity, making data resulting from their 
use difficult to interpret.  However, a major step forward in studies of Rho GTPase signaling 
came with the development of NSC23766, a specific and direct Rac1 inhibitor (Gao et al., 2004).  
NSC23766 is a first-generation small molecule inhibitor which disrupts Rac1's ability to bind to 
Rac1-specific GEFs Trio and Tiam1 without interfering with RhoA or Cdc42 activity (Table 
1.2).  Importantly, this molecule has opened the door for the development of new small molecule 
inhibitors targeting the Rho GTPase pathway that could be used to target Rho proteins directly in 
various pathological situations. 
 As expected, due to its roles in a multitude of biological processes, Rac1 is known to 
contribute to pathological conditions such as hypertension, mental retardation, neurodegenerative 
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disorders, as well as several cancer types. Hypertension, a leading contributor to cardiovascular 
mortality, is characterized by increased sensitivity of blood pressure to salt.  Interestingly, 
Shibata and colleagues (2011) recently showed that a high salt diet can activate Rac1 in the 
kidneys of a salt-sensitive hypertensive rat model.  In addition, inhibition of Rac1 with 
NCS23766 prevented hypertension and renal damage associated with increased salt loading 
(Shibata et al., 2011).    Also, Rac1/WAVE signaling has been implicated in the regulation of the 
epithelial Na
+
 channel (ENaC), which is a major effector impacting systemic blood pressure and 
volume, and is responsible for Na
+ 
reabsorption in the aldosterone-sensitive nephron.  Data 
revealed that Rac1/WAVE, but not Cdc42/WASP, was able to increase ENaC activity and these 
elevations could be decreased with the addition of NSC23766  (Karpushev et al., 2011).  These 
results highlight the importance of Rac1 in cardiovascular disease as well as lend support to the 
use of NSC23766 for therapeutic intervention.  
 Rac1 is also gaining increasing attention for its involvement in several types of 
neurological problems.  First, several studies have suggested important roles for Rac1 in the 
development of Alzheimer's disease (AD).  In human patients, Rac1, along with increased 
cytoskeletal abnormalities, were shown to be increased in those with AD versus age-matched 
controls (Zhu et al., 2000).  It has also been suggested that active Rac1, acting as a important 
component in  amyloid - beta (Aβ) -induced reactive oxygen species (ROS) production, may 
aggravate AD (Lee et al., 2002).  Other studies demonstrate that Rac1 may modulate Aβ levels 
by altering γ-secretase activity, a critical factor in amyloid precursor protein (APP) cleavage 
(Désiré et al., 2005; Gianni et al., 2003).  Interestingly, dominant negative Rac1 mutants (COS-7 
cells) or NSC23766-treated hippocampal neurons show reduced γ-secretase activity as well as 
decreased APP protein and mRNA levels (Boo et al., 2008; Wang et al., 2009).  
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  Aside from AD, a possible role for Rac1 in depression and stress-related disorders has 
recently emerged.  In rodent models, chronic stress (depression) induces functional and structural 
plasticity in several brain regions, specifically within the nucleus accumbens, the brain's reward 
center.  As Rac1 is a well established modulator of synaptic structure, Golden and colleagues 
(2013) investigated its role in depression-induced synaptic remodeling in both animal models 
and post-mortem patients with clinically diagnosed major depressive disorder.  Their work 
demonstrated a reduction in Rac1 expression following chronic stress in both animals and 
humans and, at least in rodents, stress resulted in the formation of immature stubby excitatory 
spines.  Moreover, overexpression of constitutively active Rac1 could reverse depression-related 
behaviors and reduce the density of immature spines in animal models (Golden et al., 2013). 
 Like other Rho proteins, deregulation of Rac1 can promote initiation and/or progression 
of various types of cancer. Analysis of malignant breast, colon and lung tissue has revealed 
overexpressed Rac1 protein levels compared to benign tissue (Fritz et al., 1999). Rac1b, a splice 
variant of Rac1 which exhibits accelerated GDP/GTP exchange and does not interact with 
RhoGDI, is overexpressed and promotes cellular transformation in breast and colon cancers 
(Schnelzer et al., 2000; Singh et al., 2004).  In addition, increased expression of Tiam1, a 
specific Rac1-GEF, is strongly correlated with invasiveness and poor prognosis in breast tumors 
(Adam et al., 2001; Minard et al., 2004).  Specifically, Tiam1 can promote epithelial to 
mesenchymal transition (EMT) due to its ability to modulate E-cadherin based cell-cell 
adhesions (Hordijk et al., 1997).  Interestingly, NSC23766, which competes with Tiam1 for the 
Rac1-GEF binding site, has been shown to inhibit migration (Zuo et al., 2006) and slow breast 
cancer cell growth through induction of G1 cell cycle arrest (Yoshida et al., 2010). In addition, 
data also reveals that Rac1 effector PAK is overexpressed or hyperactivated in more than 50% of 
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human breast tumors (Balasenthil et al., 2004). Such an increase in activity of either PAK or 
IQGAP has been shown to promote migration, invasiveness and anchorage-independent growth 
(Lozano et al., 2008; Noritake et al., 2004; Vadlamudi et al., 2000).   
 Clearly, Rac1 has tremendous biological significance for both normal cellular functioning 
and in the development of human pathology and, like RhoA, is becoming an important target for 
therapeutic intervention in a variety of human conditions. 
 
D. Cdc42 
 Cell division cycle protein 42 (Cdc42) was first identified and characterized in the yeast 
species Saccharomyces cerevisiae as a major regulator of cell polarity and budding (Johnson and 
Pringle, 1990).  Since that time, Cdc42 has been shown to be highly conserved across species 
and integrally involved in establishment of polarity as well as cellular morphogenesis (Boureux 
et al., 2007; Nobes and Hall, 1995).  Functionally, when compared to RhoA and Rac1, the Cdc42 
subclass is seemingly more diverse.  In addition to its most characterized role in the formation of 
filopodia via actin cytoskeleton modulation, Cdc42 also plays important roles in gene 
transcription, cell cycle progression, vesicle trafficking, cell polarity, cell adhesion and motility 
(Cerione, 2004; Hall, 1998; Johnson, 1999; Lamarche et al., 1996).   
 In order to accomplish this multitude of tasks, Cdc42 signals through several major 
downstream effectors including partitioning-defective proteins (Par6, Par3, Par2), Wiskott-
Aldrich syndrome protein (WASP) and its common effectors with Rac1, PAK and IQGAP (Fig. 
3C).  WASP and its neuronal isoform N-WASP interact with active (GTP-bound) Cdc42 to 
modulate actin polymerization in a similar manner as Rac1 effector WAVE.  Specifically, 
WASPs directly interact with both profilin, an actin-binding protein, and the Arp2/3 complex to 
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promote actin assembly and filopodia formation (Ma et al., 1998; Machesky and Insall, 1998; 
Rohatgi et al., 1999).  Par proteins are well known regulators of cell division and Cdc42-
mediated cell polarity (Gotta et al., 2001; Kay and Hunter, 2001).  When activated, Cdc42 can 
regulate the formation of the Par3-Par6-aPKC (atypical protein kinase C) complex which is 
important in the establishment of polarity of epithelial cells undergoing cell migration (Lin et al., 
2000) as well as mediating microtubule stabilization at the cell front and orienting the Golgi and 
microtubule-organizing center (MTOC) in cells undergoing directional migration (Etienne-
Manneville and Hall, 2003). 
 The study of Cdc42 has greatly lagged behind that of RhoA and Rac1 due to early 
embryonic lethality in genetic models and deficiencies in the molecular tools available to further 
dissect Cdc42 signaling pathways.  Studies performed with constitutively active and dominant 
negative  Cdc42 mutants revealed that Cdc42 is critical for actin-based filopodia formation in 
embryonic stem cells, fibroblasts and neurons (Chen et al., 2000a; Yang et al., 2006).  Complete 
deletion of Cdc42  was found to be embryonic lethal very early in embryogenesis (E6.5) and 
severely disrupted actin cytoskeletal organization due to improper actin polymerization (Chen et 
al., 2000a).  Several conditional KO mice of Cdc42 have since been generated and demonstrate 
that, physiologically, the function of Cdc42 depends upon cell type and stage of development.  
For example, conditional deletion of Cdc42 within the brain, aside from also being lethal, leads 
to decreases in axon numbers and brain size and malformed axonal tracts (Garvalov et al., 2007).    
 Like Rac1, small molecules specifically targeting Cdc42 have been lacking and have 
greatly limited our understanding and ability to manipulate Cdc42.  Although Cdc42 activation 
can be induced by epidermal growth factor (EGF), bacterial cytotoxic necrotizing factor (CNF) 
toxins, or bradykinin, these methods are either nonspecific for Cdc42 (EGF and CNF) or indirect 
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and not well understood (bradykinin, Table 1.1) (Flatau et al., 1997; Kozma et al., 1995; Ridley, 
Paterson, Johnston, Diekmann and Hall, 1992).  Until recently the only available Cdc42 
inhibitors were the small molecules secramine B (Pelish et al., 2006) and Pirl1 (more recently 
known as CASIN; Peterson et al., 2006), which were identified from a large scale screening of 
compounds capable of inhibiting membrane traffic or PIP2-induced actin polymerization, 
respectively.  Although these molecules have been available for a considerable time, they have 
not been extensively cited (Pirl/CASIN: 3 publications; secramine B: 9 publications).  The 
primary reason for this is probably due to the fact that the mechanisms are not well understood 
and the molecules are not easily acquired.  Both compounds, although structurally unrelated, 
appear to promote sequestration of RhoGDI-bound Cdc42 thereby preventing its association with 
membranes and subsequent GTP binding (Pelish et al., 2006).  Importantly, our laboratory has 
undertaken a rigorous screening of small molecules that potentially fit into the Cdc42 binding 
pocket critical for association with GEF's.  Specifically, we targeted the interaction between 
intersectin (ITSN), a Cdc42 specific GEF and adaptor molecule linking endocytosis to WASP-
induced actin polymerization, and the GEF binding pocket of Cdc42 (Smith et al., 2005).  From 
this screening, a compound designated as ZCL278 was identified as the first specific and direct 
small molecule inhibitor of Cdc42 (Table 1.2; Friesland et al., 2013).  This molecule has filled a 
critical gap in the Rho GTPase field and will allow us to better understand Cdc42 signaling in 
general as well as how it correlates to the pathological condition.  ZCL278 will be discussed in 
great detail in Chapter III of this dissertation. 
 Cdc42, like other Rho proteins, contributes to the formation of several pathological 
conditions.  First, it is known to regulate cardiovascular and blood functions.  Conditional KO of 
Cdc42 in the mouse heart resulted in hypertrophy in response to both physiological and 
 18 
 
pathological stimulation (Maillet et al., 2009).  Cdc42 may also play an important role in 
microvascular permeability.  Constitutive Cdc42 activation has been shown to impede 
microvascular endothelial barrier function following thrombin insult, and increased permeability 
(Kouklis et al., 2004).  Interestingly, some research also suggests that this reduction in 
permeability may result from destabilization of cadherin complexes which in turn may modulate 
Cdc42 activation (Broman et al., 2006).  In addition,  Cdc42 overexpression, due to genetic 
Cdc42GAP deletion, has been shown to promote anemia and blood progenitors demonstrate 
impaired F-actin assembly, migration and adhesion (Wang et al., 2006).   
 As Cdc42 is a well documented positive regulator of neuritogenesis, it is not 
unreasonable to suspect its involvement in neurological disorders (Govek et al., 2005).  In fact, 
intersectin (ITSN), a prominent Cdc42-specific GEF, has been linked to Down syndrome.  The 
intersectin gene, like Down syndrome, localizes to chromosome 21 (21q22) and when mutated, it 
is associated with damaged vesicle trafficking and endocytic function, which also happens to be 
characteristic of early endocytic anomalies that are reported in Down syndrome brains (Guipponi 
et al., 1998; Hussain et al., 2001).  Furthermore, Down syndrome is frequently associated with 
early incidence of AD.  Specifically, in AD, abnormal and enlarged early endosomes are located 
at the site of β-amyloid (Aβ) peptide generation and processing of several proteins involved in 
AD (Cataldo et al., 2000).  Thus, there may be an important link between Rho GTPase signaling, 
Down syndrome, and AD.  Additionally, mutations in FGD1, a Cdc42-specific GEF, results in 
faciogenital dysplasia or Aarskog-Scott syndrome.  This syndrome is characterized by short 
stature, mental retardation, as well as facial, skeletal, and urogenital abnormalities (Pasteris et al., 
1994; Zheng et al., 1996).  More recent studies have also implicated aberrant Cdc42 signaling in 
schizophrenia.   In post mortem human brain specimens of subjects with schizophrenia, Cdc42 
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protein and mRNA expression was found to be decreased as compared to that of non-
schizophrenic patients.  Furthermore, spine density, which has long been attributed to Cdc42-
mediated pathways, were found to be lower in specific layers within the dorsaolateral prefrontal 
cortex (Ide and Lewis, 2010). 
 Deregulation of Cdc42, like other Rho proteins, has been increasingly implicated in 
various cancer types and in processes that promote cancer development and progression such as 
transformation and metastasis.  Cdc42 overexpression has been described in melanoma (Tucci et 
al., 2007), non-small lung (Liu et al., 2009), colorectal (Gómez Del Pulgar et al., 2008), breast 
(Fritz et al., 2002), and testicular (Kamai et al., 2004) cancers.  Loss of function/deregulation in 
several Cdc42 GAPs have been observed in several cancer types.  Specifically, DLC-1, a GAP 
that modulates GTP hydrolysis in both RhoA and Cdc42, was demonstrated to be down 
regulated in breast and lung cancers and was associated with increased cell proliferation and 
tumor formation (Durkin et al., 2007). In addition, overexpression of the Cdc42 GEF, 
ARHGEF9, is correlated with increased epithelial to meschymal transition (EMT) due to 
increased Cdc42 activation and reduced E-cadherin expression (Chen et al., 2010).  Importantly, 
cells that have undergone transformation lack proper polarity.  Importantly, the Par3/Par6/aPKC 
complex, which is associated with tight junction structures, is required for the maintenance of 
cell polarity (Joberty et al., 2000; Qiu et al., 2000).  This process implicates the Cdc42-dependent 
activation of the Par3/Par6/aPKC complex as a possible contributor to malignant cell 
transformations.  Although the oncogenic capabilities of Cdc42 are still under investigation, its 
involvement in cell division, cell cycle progression, and proliferation support its role in cancer 
formation, invasion and metastasis (Gjoerup et al., 1998; Yasuda et al., 2006; Hill et al., 1995; 
Debidda et al., 2005).   
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 As an extremely diverse Rho protein, Cdc42 subclass is a very important regulator of a 
multitude of critical cellular processes, and as such, it is an important component in many 
clinical and developmental problems.  Identification of small molecule modulators of Cdc42 will 
be extremely important for furthering our understanding of Cdc42 signaling and/or its 
mechanisms in human pathology. 
 
E.  Rho GTPase cross-talk  
 Multiple studies, beginning with work done by Ridley and Hall (1992), have 
demonstrated that cross-talk regulation or Rho GTPase regulation by other Rho GTPases, does 
occur.  Nobes and Hall (1995) demonstrated that a hierarchical relationship between RhoA, 
Rac1, and Cdc42 exists in quiescent fibroblasts. Studies revealed that active Cdc42 can stimulate 
Rac1, activated Rac1 can stimulate RhoA, Cdc42 and RhoA antagonize each other, and RhoA 
can antagonize Rac1 (as reviewed by Giniger, 2002; Lim et al., 1996; Nobes and Hall, 1995; 
Sander et al., 1999).  According to Guilluy et al. (2011), this cross regulation can happen in 
several ways: (1) through RhoGEFs or RhoGAPs, (2) through RhoGDIs, or (3) through 
regulation of downstream signaling pathways (Guilluy et al., 2011). 
 The best documented and well understood example of Rho protein crosstalk is the 
antagonistic relationship between RhoA and Rac1.  During cell migration, high Rac1 activity is 
found at the leading edge of cells, while RhoA activity is high at the opposite, retracting tail of 
the cell (Ridley et al., 2003).  This activity has been shown to be maintained by the fact that Rac1 
can alter RhoGAP activity, thereby inhibiting RhoA (Nimnual et al., 2003).  Additionally, the 
Rac1 effector PAK can impair activation of ARHGEF1, a RhoA GEF, thus adding another 
avenue for RhoA suppression (Rosenfeldt et al., 2006).  Alternatively, RhoA can antagonize 
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Rac1 activity.  For example, ROCK, the major RhoA effector, can inhibit Rac1 activity by 
phosphorylating and activating the Rac1-specific GAP protein, FilGAP, thus promoting 
increased GTP hydrolysis (Ohta et al., 2006).  Cdc42 and RhoA are also spatially exclusive  
from each other and modulate actin assembly and organization in different ways suggesting a 
similar antagonistic relationship as that of Rac1 and RhoA (Benink and Bement, 2005).  
Although the exact mechanism remains unclear, probably due to difficulties and deficiencies in 
specific Cdc42 activators and inhibitors, some studies suggest that Abr, a Bcr-related protein that 
contains both a GEF domain, specific for RhoA, Rac1, and Cdc42, and a GAP domain specific 
for Rac1 and Cdc42 (Chuang et al., 1995) could be involved.  Recent work demonstrated that 
Abr regulates Cdc42 inactivation and RhoA activation during wound healing in Xenopus 
oocytes, although the precise mechanism still remains unclear (Vaughan et al., 2011).  Novel 
roles of RhoGDIs have recently been described as important contributors to Rho protein 
crosstalk.  Interestingly, RhoGDI1, one of the three conventional RhoGDIs that universally bind 
most Rho GTPases, can protect prenylated Rho proteins from proteosome-dependent degradation 
(Boulter et al., 2010).  Moreover, RhoGDI1 is expressed at levels that reflect the sum of  all Rho 
family members, indicating that it may create competition between family members for binding 
(Michaelson et al., 2001).  In fact, Boulter (2010) demonstrated that overexpression of one Rho 
protein could displace another from RhoGDI1, and facilitate their inactivation.  Thus, it is clear 
that Rho GTPase cross talk can complicate our understanding and interpretations of Rho protein 
function, but also is likely very important for fine tuning of Rho GTPase-dependent signaling 
cascades.  
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F.  Cisplatin 
First described by Rosenberg in 1965, cisplatin or cis-dichlorodiammineplatinum (II) is currently 
one of the most effective and widely used chemotherapeutic agents.  Since its approval in 1978 
for clinical use, cisplatin has been a successful oncological tool to treat various forms of cancer 
including testicular, ovarian, cervical, bladder, head and neck, lung, breast, prostate and 
colorectal (Boulikas and Vougiouka, 2003; Higby et al., 1974; Wozniak and Blasiak, 2002).   
 Cisplatin is the first member of a family of platinum-based drugs which also includes 
carboplatin and oxaliplatin.  Structurally, the cisplatin molecule is composed of a platinum ion 
surrounded by four ligands (two amines and two chlorides) arranged in a square, where both 
chloride ligands and both amine ligands are beside each other in cis formation (Fig. 1.5).  The 
trans isomer of this molecule is clinically ineffective.  As depicted in Fig. 1.5, the cytotoxic 
mechanism of cisplatin relies on its ability to form inter- and intra-strand DNA cross-links 
(Eastman, 1990; Zwelling and Kohn, 1979) .  Due to the high concentration of chloride ions 
outside a cell, the cisplatin molecule is relatively stable.  However, as cisplatin diffuses into a 
cell where chloride concentrations are much lower, the chloride ions are lost and quickly 
replaced by water molecules, rendering them a positive, reactive species that can form bonds 
with DNA bases (as reviewed by Boulikas and Vougiouka, 2003).  Due to its cis geometry, the 
newly aquated cisplatin molecule can easily form cross-links on the same strand of DNA or on 
adjacent sites between two strands of DNA.  1,2-intrastrand cross-links between purine bases are 
the predominate product of cisplatin administration.  These include 1,2-intrastrand cross-links 
between guanine (GpG) bases which form nearly 90% of the adducts and the less common 1,2-
intrastrand cross-link between adenine and guanine (ApG) bases (Fichtinger-Schepman et al., 
1985; Kelland, 1993).  The formation of DNA cross-links lead to major local distortions of DNA 
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structure, causing the helix to bend and/or unwind and ultimately initiates the process of 
apoptosis (as reviewed by Wozniak and Blasiak, 2002). 
 Typically, a cisplatin treatment regimen involves a series of intravenous injections that 
are administered to the patient every three to four weeks at a dose range of 20-120 mg/m
2 
which 
depends on the condition of the patient, type of cancer being treated and whether other cytotoxic 
agents are co-administered (Boulikas and Vougiouka, 2003).  Although cisplatin has greatly 
enhanced our ability to treat several types of cancer it's cytotoxic effects are not limited to 
neoplastic tissue.  Thus, a variety of side effects can limit a chemotherapy patient's ability to 
tolerate appropriate cisplatin regimens.  Like many other chemotherapeutics which target rapidly 
dividing cells, cisplatin patients exhibit hair and weight loss, nausea and vomiting, 
immunosuppression, as well as reduced blood and platelet production in bone marrow 
(myelosuppression).  In addition, more specific side effects include hearing loss (ototoxicity), 
kidney damage (nephrotoxicity), and neuronal damage (neurotoxicity; Florea and Büsselberg, 
2011).  To date,  the best management strategies for these side effects are to either increase 
cisplatin clearance with increased intravenous hydration with the option of osmotic diuretics or 
to reduce dosage (Tsang et al., 2009). 
 Peripheral neurotoxicity is the most common dose-limiting problem associated with 
cisplatin therapy.  Chemotherapy-induced peripheral neuropathy (CIPN) develops in up to 50% 
of cisplatin patients (Gutiérrez-Gutiérrez et al., 2010; Strumberg et al., 2002; van der Hoop et al., 
1990a) and has the tendency to be more prevalent and/or severe in patients with compromised 
immune systems, diabetes or alcoholism (Schloss et al., 2013).  Onset of CIPN often begins after 
cumulative doses of 300 mg/m
2 
or more (Gregg et al., 1992) and initially presents in a "glove and 
stocking" fashion whereby symptoms begin in distal extremities and progress proximally  (Jaggi 
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and Singh, 2012; Kaley and Deangelis, 2009).  Typical CIPN symptoms include loss of vibration 
sense, paresthesias, numbness, tingling and burning sensations, decreased reflexes, and 
decreased sense of vibration (Beijers et al., 2012; McWhinney et al., 2009).  Importantly, CIPN 
incidence and severity is dose dependent (Gregg et al., 1992) and following dose reduction or 
treatment cessation, neurological symptoms may gradually improve, persist for a short time, or 
can be permanent (van der Hoop et al., 1990b).  Clinical CIPN diagnosis has been somewhat 
complicated by the lack of a universal toxicity scale.  For example, neurologists tend to prefer 
the Total Neuropathy Score (TNS) which compiles information pertaining to motor, sensory and 
autonomic signs and symptoms, determination of vibration perception thresholds and 
electrophysiological examinations, while oncologists prefer the  National Cancer Institute-
Common Toxicity Criteria (NCI-CTC) which provides a much less detailed description of 
clinical and pathological aspects of CIPN (Schloss, et al., 2013).  Therefore,  this lack of 
standardization may result in the under diagnosis of CIPN.  Mechanistically, it remains unclear 
how CIPN develops, as neurons are not a mitotic population of cells and the primary cisplatin 
targets are rapidly dividing cells.  CIPN and a potential mechanism will be further addressed in 
Chapter II. 
 
G.  Rationale for current studies  
 Given that Rho proteins are involved in a variety of regulatory functions within cells and 
implicated in a multitude of human pathological conditions, they are very attractive, exploitable 
targets for drug discovery and intervention. Our laboratory has become increasingly interested in 
understanding the mechanisms involved in cisplatin-induced peripheral neurotoxicities. More 
precisely, our studies aim to elucidate how Rho GTPase involvement in CIPN contributes to 
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neurodegeneration and how targeted Rho protein suppression may be used as a preventative or 
recovery measure from cisplatin-induced neuronal damage. 
 Initially, data derived from primary neuronal cultures treated with several anti-neoplastic 
agents known to lead to clinical neurotoxicity, showed marked morphological abnormalities in 
actin-based structures (James et al., 2008).  Other unpublished work in PC-3 cells, metastatic 
human prostate cancer cells, and PZ-HPV-7 cells, non-cancer human prostatic epithelial cells, 
revealed that cisplatin could also induce actin-mediated process retraction and induction of 
morphological disruption prior to apoptosis in non neuronal cell populations (Fig. 1.4; 
unpublished work, Friesland and Lu, 2010).  In addition, our other preliminary experiments 
sought to understand if cisplatin targeted other actin-mediated events such as cytokinesis.  Flow 
cytometry was used to analyze the cell cycle in H522 lung cancer cells that were synchronized in 
G1/S phase by aphidicolin (Fig. 1.6B) or G2/M phase with nocodozole (Fig. 1.6C).  When 
released from arrest both aphidicolin and nocodozole-treated cells were able to progress through 
the cell cycle (Fig. 1.6D-E).  However, synchronized H522 cells treated with cisplatin displayed 
a G1 to S phase block, closely resembling aphidicolin-induced arrest, in both treatment groups 
(Fig. 1.7A-B).  Furthermore, this effect was only minimally recoverable following release from 
cisplatin (Fig. 1.7C-D), indicating that cisplatin preferentially targets a G1 to S progression and 
not the actin-mediated cytokinesis process.  Taken together, these preliminary results supported 
the actin cytoskeleton as an alternate target of cisplatin, aside from the widely accepted DNA-
targeting cisplatin mechanism (Fig. 1.5; unpublished work, Friesland and Lu, 2010). 
 Moreover, work by James et al. (2008) showed that inhibition of Rho pathway signaling 
with LM11A-31 (p75
NTR
 ligand mimetic) and Y-27632 (Rho kinase inhibitor) could not only 
decrease RhoA expression but also reverse cisplatin-induced neurodegeneration in primary 
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neuronal cultures.   These results led James et al. (2010) to develop an in vivo model of CIPN in 
order to test the efficacy of using Y-27632-mediated ROCK suppression as a possible recovery 
method from cisplatin-induced neurodegeneration.  Their data reveal that 15 weeks of cisplatin 
treatment could generate measureable reductions in peripheral nerve sensitivity as well as 
disruptions in axonal integrity.  Finally, during a one-month recovery period following cisplatin 
injections, mice that received Y-27632 were able to demonstrate both functional recovery in 
hindpaw sensitivity and increased levels of myelination as compared to mice receiving only 
saline during recovery (James et al., 2010).   
  Although this work supported RhoA activation as a major contributor to the development 
of CIPN, it did not definitively confirm it.  Furthermore, it would be more clinically relevant to 
patients undergoing cisplatin chemotherapy to focus on preventing CIPN from developing during 
treatment.  Therefore, in the current study, we sought to modify the previous CIPN mouse model 
into a preventative in vivo study whereby we targeted RhoA signaling upstream with high and 
low doses of LM11A-31 concomitant with cisplatin treatment.  From these studies we were able 
to address questions of RhoA activity and expression due to treatment with cisplatin alone and 
with cisplatin plus LM11A-31, as well as analyze the morphology of peripheral nerve fibers 
more closely.  In addition, through protein analysis of peripheral nerve tissue and collected 
primary neuronal lysates we were able to generate data implicating SHP2 phosphatase, which 
modulates tyrosine dephosphorylation of p190-B RhoGAP to activate RhoA (Kontaridis et al., 
2004; Sordella et al., 2003),  in the CIPN mechanism. 
 Finally, as it has been well established that Rho proteins significantly influence each 
other, it is critical for the understanding of CIPN as well as other pathological conditions, to 
investigate cross-talk between Rho family members.  However, to date this has been a difficult 
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task to accomplish as small molecules targeting the Cdc42 subclass of Rho proteins has lagged 
far behind those of RhoA and Rac1.  Therefore, we undertook a similar strategy as was used to 
develop the Rac1 inhibitor, NSC23766 (Gao et al., 2004), in order to identify the first specific 
and direct Cdc42 inhibitor, ZCL278.  Our studies have confirmed that this cell-permeable, easily 
synthesized compound could decrease GTP-bound Cdc42 and microspike formation as well as 
inhibit Cdc42-dependent cell migration and neuronal branching and disrupt Golgi organization 
(Friesland et al., 2013).  Our identification of ZCL278 will allow further dissection of Cdc42-
mediated signaling pathways and mechanisms by which Cdc42 can contribute to cancer, CIPN, 
and other neurodegenerative problems, in addition to investigations of how it is able to influence 
and modulate other Rho family members. 
 
H.  Statement of Hypothesis and Specific Aims 
Hypothesis 
RhoA pathway suppression in conjunction with cisplatin chemotherapy will prevent 
neurodegeneration and provide an effective combinatorial therapy in a mouse model of cisplatin-
induced peripheral neuropathy. 
 
Specific Aim I: 
To investigate RhoA expression and activity in the sural nerve of the cisplatin-treated mouse as 
well as the effects of a p75
NTR
 ligand mimetic and upstream RhoA inhibitor, LM11A-31 as a 
method to prevent cisplatin-induced neurotoxicity. 
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Pharmacological treatments:  Age matched (3 months) C57/BL6 mice were treated with either 
saline or cisplatin every 14 days for 10 weeks.  In addition, two additional groups of 
cisplatin-treated mice received either a high or low dose of LM11A-31. 
Von Frey/Semmes-Weinstein sensory threshold testing:  Von Frey/Semmes-Weinstein 
monofilaments were used to stimulate the hindpaw and evaluate a threshold force needed 
to elicit a sensory response in animals in all four treatment groups. 
Immunofluorescent analysis of peripheral nerve tissue:  Harvested sural nerves were removed 
from each animal following 10 weeks of treatment.  Frozen cryosections of sural nerve 
cross-sections were prepared and immunolabeled with total (active and inactive) and 
phosphorylated (inactive) RhoA antibodies in order to compare RhoA activity due to 
treatment. 
Morphological analysis of peripheral nerve tissue:  Sural nerve cross-sections obtained from 
frozen cryosections were examined by phase-contrast microscopy.  Axon, myelin, and 
total fiber (axon + myelin) areas and shapes were measured and compared between 
groups. 
Protein analysis of peripheral nerve tissue:  Harvested after 10 weeks of treatment, sciatic nerves 
were homogenized and subjected to Western blot analysis with antibodies against total 
and phosphorylated RhoA, total and phosphorylated SHP2, and GAPDH. 
Primary neuronal cultures: Primary mouse cortical neurons were prepared and treated with 
either calpeptin, a known RhoA activator, or cisplatin.  In addition, groups of neurons 
also received LM11A-31 in addition to both calpeptin or cisplatin. 
Neuronal morphological analysis:  Treated neurons were fixed and actin-based structures were 
visualized with phalloidin.  Nuclei were stained with Hoescht 33258.  Neuronal images 
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were captured using a Zeiss Axiovert S100 fluorescent light microscope (Carl Zeiss, 
Thornwood, NY) and branches and sprouts were counted and measured using 
MetaMorph™ 4.6 imaging software systems (Molecular Devices, Sunnyvale, CA). 
Neuronal RhoA Immunofluorescence:  Treated neurons were fixed and immunolabeled with total 
and phosphorylated RhoA antibodies. 
Analysis of protein expression in neuronal lysates:  Lysates were collected from drug-treated 
mouse primary neuronal cultures and subjected to Western blot analysis. Blots were 
probed for antibodies against phosphorylated RhoA and phosphorylated SHP2. 
Statistical analysis: t-test analysis was performed and p-values were designated for each 
experiment, each of which were repeated a minimum of three times.  Any null hypothesis 
with probability level less than 95% was rejected. 
 
 Specific Aim II: To identify and characterize small molecule inhibitors of Cdc42 activation for 
further determination of the roles of cross talk between Rho subfamilies in cisplatin-induced 
peripheral neurotoxicity. 
Virtual screening:  A database consisting of 197,000 compounds was virtually screened for small 
molecules that can disrupt the interaction of Cdc42 with its specific GEF intersectin 
(ITSN).  The top ranked 50,000 molecules were then subjected to more stringent SP 
(standard precision) docking, after which the top ranked 100 molecules were manually 
inspected to select 30 compounds for in vitro and biological testing. 
Synthetic procedures:  Top ranking 100 compounds were synthesized and then purified by 
column and high performance liquid chromatography (HPLC). 
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Fluorescence titration:    Lyophilized Cdc42 protein was reconstituted and placed in a quartz 
cuvette, to which aliquots of ZCL278 were added.  The fluorescent wavelength of 
tryptophan (350 nm) was measured after each ZCL278 addition.  Titration curves were 
generated to calculate Kd. 
Surface plasmon resonance:  In order to assess direct binding of ZCL278 and Cdc42, ZCL278 
was covalently immobilized to purified Cdc42 on a CM5 chip and varying ZCL278 
concentrations were added in order to determine Kd. 
Determination of pKa values of ZCL278: The pKa of ZCL278 was calculated by dissolving 
ZCL278 in water and titrating with either HCl or varying DMSO concentrations. 
Measurement of the solubility of ZCL278:  Solubility of ZCL278 was determined by measures of 
UV absorption of saturated ZCL278 solutions. 
p50RhoGAP or Cdc42GAP assay: Inorganic phosphate produced as a result of GTPase activity 
was measured using a p50RhoGAP or Cdc42GAP assay whereby Cdc42 was preloaded 
with either GTP or ZCL278, and then stimulated with Cdc42GAP. 
Immunofluorescent characterization of ZCL compounds:  Serum-starved Swiss 3T3 cells were 
treated with or without Cdc42 activator, RhoA activator, Rac activator, ZCL series 
compounds, Y-27632, or NSC23766.  Cdc42-mediated microspike formation was then 
analyzed in phalloidin stained cells. 
Western blot analysis of ZCL278:  PC-3 were treated with a Cdc42 activator or  a time course of 
ZCL278.  Lysates were then collected, subjected to Western blot analysis, and probed 
with antibodies against phospho-Rac1/cdc42 (Ser71), phosphorylated WASP, and 
GAPDH. 
 31 
 
G-LISA®: Cdc42 activation and inactivation was directly assessed in serum starved Swiss 3T3 
cells which were treated with or without the Cdc42 activator, ZCL278 or NSC23766 
using a G-LISA®, an ELISA-based assay that allows a quantitative determination of the 
levels of GTP-bound (active) Cdc42 in cellular lysates.    
Active Cdc42 Immunofluorescence:  Serum starved Swiss 3T3 cells were treated with ZCL278 or 
NSC23766 and then stimulated with a Cdc42 activator.  Cells were then immunolabeled 
with an active Cdc42 and a phosphorylated RhoA antibody, in order to elucidate the 
effect of ZCL278 on Cdc42 activity in vitro. 
GM130 Immunofluorescence:  Serum starved Swiss 3T3 cells were treated with ZCL278 or 
NSC23766 and then stimulated with a Cdc42 activator.  The influence of ZCL278 on 
Golgi organization was investigated by immunostaining for GM130, a cis-Golgi matrix 
protein. 
Wound Healing Assay:  Serum starved PC-3 cell monolayers were scratched and then treated 
with or without a Cdc42 activator, ZCL278, or NSC23766.  After 24 hours, distance of 
migration was measured. 
Primary neuron morphology:  Mouse primary cortical neurons were harvested, cultured and 
treated with either DSMO or ZCL278.  Cells were then fixed, probed with phalloidin, and 
branching was analyzed. 
Primary neuron time-lapse imaging:  Mouse primary cortical neurons were treated with either 
DSMO or ZCL278 for 10 minutes, during which they were recorded by time lapse light 
microscopy.  Growth cones and filopodial dynamics were observed.  Images were 
captured and analyzed with MetaMorph™ 4.6 imaging software systems (Molecular 
Devices, Sunnyvale, CA). 
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Statistical analysis: t-test analysis was performed and p-values were designated for each 
experiment, each of which were repeated a minimum of three times.  Any null hypothesis 
with probability level less than 95% was rejected. 
 
I.  Significance 
 Rho GTPases are crucial regulators for a variety of cellular functions and aberrant 
activity or regulation of Rho proteins have been critically linked to a multitude of human 
pathologies.  For these reasons, Rho proteins (including the major family members RhoA, Rac1 
and Cdc42) have emerged as promising therapeutic targets.  In the current study, we focus on 
Rho GTPase inhibition as a putative combinatorial therapy that could be used alongside 
traditional chemotherapeutic cancer treatment.  Traditional chemotherapy is an effective method 
of cancer cell eradication; however, its cytotoxic effects are not limited to cancerous cells.  
Neurotoxicity is known to occur with use of several anti-neoplastic agents including the 
platinum-based compound cisplatin, and can be debilitating and dose-limiting for patients.  
Using a clinically relevant dose of cisplatin, our laboratory has developed a mouse model of 
cisplatin-induced peripheral neuropathy (CIPN).  Using this model, we investigated the 
neuroprotective advantages of RhoA suppression in conjunction with cisplatin treatment as a 
possible method of CIPN prevention.  In addition, this project focuses on filling a major gap in 
the understanding of Cdc42, through development of a novel small molecule inhibitor, ZCL278.  
Importantly, using ZCL278 we will be able to further dissect Cdc42 signaling pathways to 
understand the roles that Cdc42 plays in various diseases and disorders, including CIPN. 
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Figure 1.1  The Rho GTPase Cycle. 
Rho GTPases cycle between an inactive GDP bound state and an active GTP bound state and are 
regulated by GTPase activating proteins (GAPs; inactivate), guanine nucleotide exchange factors 
(GEFs; activate) and guanine nucleotide dissociation inhibitors (GDIs), which bind to the 
inactive (GTP-bound) protein and prevent its activation.  
 
 
 
 
 
 
 
 
 
 
  
 35 
 
 
 
 
 
 36 
 
Figure 1.2  Rho GTPase signaling promotes characteristic actin-based structures. 
 
External signals transduced from membrane receptors (integrins, G-protein coupled receptors, 
ion channels, growth factor receptors) promote activation of RhoA, Rac1, and Cdc42 which can 
induce cytoskeletal rearrangements resulting in the formation of stress fibers, lamellipodia, and 
filopodia/microspikes, respectively. 
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Fig 1.3 Rho GTPase effector proteins and outcomes. 
 Overview of major downstream effectors of RhoA (A), Rac1 (B), and Cdc42 (C) and their 
resultant cellular outcomes. 
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Figure 1.4  Cisplatin treatment leads to retraction of cellular processes in both PC-3  and PZ-
HPV-7 cells. 
PC-3 cells, metastatic human prostate cancer cells, and PZ-HPV-7 cells, non-cancer human 
prostatic epithelial cells, were treated with DMSO (control) or 6μg/mL cisplatin for 2 or 16 
hours. Fluorescein-phalloidin staining revealed many extended processes in control cells. 
Cisplatin treatment decreased the number and length of processes (white arrowheads) after 2 
hours, which progressed to further retraction and rounded cell morphologies in both cell types 
after 16 hours. 
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Figure 1.5 Structure and proposed cisplatin mechanism of action. 
 Cisplatin is a platinum-based chemotherapeutic drug that is frequently used to treat various 
forms of cancer including testicular, ovarian, bladder, lung, and prostate cancer.  Its primary 
mechanism of action is thought to occur as a result of spontaneous hydration reactions which 
lead to the displacement of the chloride ligands which then enables the platinum atom to bind 
nucleotide bases within the DNA.  The most frequent adducts formed are the 1, 2 intrastrand 
cross-links between guanine bases.  Ultimately, these distortions of the DNA will lead to one of 
two outcomes:  (1) DNA repair or (2) apoptosis. 
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Figure 1.6 Aphidicolin suppresses G1 to S transition while Nocodazole increases G2/M 
population in H522 lung cancer cells. 
Cultures of H522 cells were used to analyze the cell cycle by flow cytometry.  Cells were 
maintained as non-treated controls (A) or treated for 20 hours with either 1μg/mL aphidicolin, 
which leads to G1/S boundary arrest (B), or 0.1 μg/mL nocodazole, which arrests the cell cycle at 
the G2/M boundary (C). Following 20 hours of 1 µg/ml aphidicolin (D) or 0.1 µg/ml nocodazole 
(E) treatment, H522 cells were released from blocks for 10 hours.  Percentages reflect the 
proportion of cells within the population at each phase of the cell cycle.  
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Figure 1.7 Cisplatin blocks G1 to S phase transition. 
H522 cells synchronized at either the G1/S boundary (A) or G2/M boundary (B) for 20 hours 
were then treated with 5 μg/mL cisplatin for 24 hours in order to further elucidate cisplatin’s 
action within the cell cycle. H522 cells synchronized with 1 µg/ml aphidicolin (C) or 0.1 µg/ml 
nocodazole (D) for 20 hours followed by cisplatin treatment for 24 hours were then released 
from cisplatin for an additional 10 hours.  
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Table 1.1  Major Rho GTPase Activators 
 
Rho 
GTPase 
         Activator Method Reference 
RhoA Lysophosphatidic 
Acid 
Indirect, non-specific 
Gα12/13 agonist 
 
(Ridley and Hall, 
1992) 
RhoA Sphingosine-1-
phosphate 
Indirect, non-specific 
Gα12/13 agonist 
 
(Hill, Wynne and 
Treisman, 1995) 
RhoA Calpeptin Indirect, specific 
SHP2 tyrosine phosphatase 
-mediated p190RhoGAP 
inhibition 
 
(Schoenwaelder et 
al., 2000) 
RhoA, Rac1, 
Cdc42 
Epidermal Growth 
Factor (EGF) 
Indirect, nonspecific 
Stimulates tyrosine kinase 
receptor EGFR 
(Ridley et al., 1992) 
 
RhoA, Rac1, 
Cdc42 
 
Bacterial cytotoxic 
necrotizing factor 
(CNF) toxins. 
 
Direct, nonspecific  
deamidates glutamine-63 of 
Rho and glutamine-61 of 
Rac and Cdc42 in their 
Switch II regions 
 
 
(Flatau et al., 1997; 
Schmidt et al., 1997) 
Rac1 Platelet-derived 
growth factor 
(PDGF) 
 
Indirect, nonspecific 
Acts through receptor 
tyrosine kinases 
(Ridley et al., 1992) 
Cdc42 Bradykinin Indirect, nonspecific 
Acts through bradykinin 
receptor-linked G-proteins  
 
(Kozma et al., 1995) 
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Table 1.2 Major Rho GTPase inhibitors 
 
Rho 
GTPase 
Inhibitor Method Reference 
RhoA, Rac1, 
Cdc42 
C3Transferase Indirect, specific 
ADP-ribosylation on 
asparagine 41 in the effector 
binding domain 
 
(Kumagai et al., 
1993) 
RhoA Fasudil Indirect, specific 
Selectively inhibits ROCK 
 
(Nagumo et al., 2000) 
(Uehata et al., 1997) 
 
RhoA Y-27632 Indirect, specific 
Selectively inhibits ROCK 
 
(Narumiya, Ishizaki 
and Uehata, 2000) 
RhoA CCG-1423 Indirect, nonspecific 
Targets MKL/SRF-
dependent transcriptional 
activation 
 
(Evelyn et al., 2007) 
RhoA LM11A-31 Direct, specific 
Blocks upstream activation 
of RhoA via the p75 
neurotrophin receptor and 
prevents dissociation from 
RhoGDI 
(Massa et al., 2006) 
    
Rac1 NSC23766 Direct, specific 
Prevents Rac1 interaction 
with specific GEF's Trio and 
Tiam1 
 
(Gao et al., 2004) 
 
Cdc42 
 
ZCL278 
 
Direct, specific 
Targets Cdc42 interaction 
with Cdc42-specific GEF 
intersectin 
 
(Friesland et al., 
2013) 
Cdc42 Pirl1 Indirect, specific 
Prevents dissociation from 
RhoGDI and GTP exchange 
 
(Peterson et al., 2006) 
Cdc42 Secramine B Indirect, specific 
Prevents dissociation from 
RhoGDI and membrane 
association 
(Pelish et al., 2006) 
  
CHAPTER II:  AMELIORATION OF CISPLATIN-INDUCED EXPERIMENTAL 
PERIPHERAL NEUROPATHY BY A SMALL MOLECULE TARGETING P75
NTR    
 
A.  Summary 
 Cisplatin is an effective and widely used first-line chemotherapeutic drug for treating 
cancer. However, many patients sustain cisplatin-induced peripheral neuropathy (CIPN), often 
leading to a reduction in drug dosages or complete cessation of treatment. Therefore, it is 
important to understand alternative cisplatin targets in peripheral nerve tissues and identify 
signaling pathways for potential intervention. Rho GTPase activation is increased following 
trauma in several models of neuronal injury. Thus, we investigated whether components of the 
Rho signaling pathway represent important neuroprotective targets with the potential to 
ameliorate CIPN and enhance current chemotherapy treatment regimens.   
      We have developed a novel CIPN model in the mouse. Using this model and primary 
neuronal cultures we examined the effects of LM11A-31, a small-molecule that blocks proNGF 
binding to the p75 neurotrophin receptor (p75
NTR
), on Rho GTPase signaling and CIPN 
reduction. Von Frey filament analysis of sural nerve function showed that LM11A-31 treatment 
prevented decreases in peripheral nerve sensation seen with cisplatin treatment. Morphometric 
analysis of harvested sural nerves revealed that cisplatin-induced abnormal nerve fiber 
morphology and the decreases in fiber area were alleviated with concurrent LM11A-31 
treatment. Cisplatin treatment increased RhoA activity accompanied by the reduced tyrosine 
phosphorylation of SHP2, which was reversed by LM11A-31. LM11A-31 also countered the 
effects of calpeptin, which activates RhoA by inhibiting SHP2 tyrosine phosphatase and reduces 
neuronal sprout numbers. Therefore, suppression of RhoA signaling by either blocking proNGF 
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binding to p75
NTR
 or by activating SHP2 tyrosine phosphatase downstream of NGF receptor 
enhances neuroprotection in our experimental CIPN mouse model. 
 
B.  Introduction 
 Cisplatin (cis-diamminedichloroplatinum), a platinum-based compound, is a widely used 
and valuable tool to suppress cancer cell proliferation and promote remission of various solid 
tumors.  The canonical cisplatin mechanism of action involves induction of inter- and intra-
strand DNA cross-links which ultimately result in apoptosis of rapidly dividing cells (Huang et 
al., 1995).   Unfortunately, cisplatin's cytotoxic effects are not limited to neoplastic tissue, as it 
frequently disrupts normal renal, gastrointestinal, hematologic, and peripheral nervous system 
function. 
 Peripheral neurotoxicity is the most common dose-limiting side effect of cisplatin, and 
often leads to dose reduction or complete cessation of effective treatment protocols.  Current data 
estimates that up to 50% of patients receiving cisplatin develop some degree of peripheral 
neurotoxicity (Gutiérrez-Gutiérrez et al., 2010; Strumberg et al., 2002; van der Hoop et al., 1990) 
as a consequence of treatment. Additionally, patients with predisposing conditions, including 
alcoholism, diabetes, vitamin B12 deficiency, or HIV/AIDS seem to be more prone to the 
neurotoxic effects of cisplatin (Schloss et al., 2013). Neuropathies associated with cisplatin are 
predominately sensory in nature and tend to present in a "glove and stocking" fashion as 
numbness, tingling, and pain that initiates in the distal extremities (Jaggi and Singh, 2012; Kaley 
and Deangelis, 2009). Typically, cisplatin-induced neuropathies are predominately sensory in 
nature, with patients presenting with paresthesias, loss of vibration sense, and decreased reflexes 
(Beijers et al., 2012).   Incidence and severity of cisplatin-induced peripheral neuropathy (CIPN) 
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is dose-dependent (Gregg et al., 1992) and may resolve or persist following treatment completion 
(van der Hoop et al., 1990). Cisplatin has been demonstrated to lead to the highest levels of 
tissue accumulation within the dorsal root ganglion (DRG) where it preferentially binds DNA 
(McDonald et al., 2005; Park et al., 2008).   Although it is apparent that there must be additional 
targets aside from DNA replication, as neurons are not a proliferating population of cells and are 
affected by cisplatin, cisplatin's precise neurotoxic mechanism remains uncertain.  Thus, it has 
become important not only to understand alternative cisplatin targets but to also explore 
signaling pathways for potential intervention.   
 In recent years, it has been well established that RhoA, a small GTPase, has increased 
activity following trauma in several models of neuronal injury (Brabeck et al., 2004; Cheng et 
al., 2008; Dergham et al., 2002; Dubreuil et al., 2003; Dubreuil et al., 2006).  Additionally,  
inhibition of the RhoA pathway has been shown to effectively treat Alzheimer's disease, stroke, 
neuropathic pain and inflammatory reactions in experimental models (Tatsumi et al., 2005 ; 
Walters et al., 2002; Zhou et al., 2003).  In vitro studies from our laboratory have demonstrated 
that Rho pathway inhibition, either upstream with a p75
NTR
 receptor ligand mimetic (LM11A-31) 
or downstream with a selective p160
ROCK
/ Rho kinase inhibitor (Y-27632), facilitates neuronal 
recovery in neuronal cultures treated with cisplatin (James et al., 2008).  Subsequent in vivo 
studies, using a CIPN mouse model, demonstrated RhoA pathway inhibition with Y-27632 could 
facilitate recovery from peripheral neuropathy induced by cisplatin treatment (James et al., 
2010).  These findings highlight the importance of RhoA signaling in the development of 
neurological problems and the possibility that inhibition may enhance current clinical treatments.   
 Neuroprotective strategies that focus on prevention, rather than recovery, are more 
clinically desirable and important for patient well-being and treatment.  In the current study, we 
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examined upstream suppression of the RhoA pathway with LM11A-31, which blocks proNGF 
binding to p75
NTR 
(Massa et al., 2006), concurrent with cisplatin treatment in the CIPN mouse.  
Using this model, we show that cisplatin-induced decreases in peripheral sensory nerve function 
can be prevented with LM11A-31. Abnormal fiber morphologies and decreases in axon, myelin, 
and fiber area observed in peripheral nerves harvested from cisplatin-treated animals could also 
be alleviated with LM11A-31 pretreatment. In addition, simultaneous LM11A-31 treatment 
reversed cisplatin-induced increases in RhoA activity and decreases in tyrosine phosphorylation 
of SHP2. In primary neuronal cultures and peripheral nerve tissue, LM11A-31 countered the 
effects of calpeptin, which activates RhoA by inhibiting SHP2 tyrosine phosphatase and reduces 
neuronal sprout numbers. RhoA inhibition through LM11A-31 leads to longer, more branched 
neurites in comparison to cisplatin alone, highlighting the importance of RhoA in the 
development of CIPN and a potential site of intervention that could be exploited clinically for 
patients undergoing chemotherapy. 
 
C.  Experimental Procedures 
C.1  Pharmacological treatments 
 Forty-four (22 male; 22 female) age-matched C57/BL6 mice (3 months; Charles River, 
Wilmington, MA) weighing an average of 24 g were obtained.  Mice were treated with either 6 
µg/g body weight cisplatin (Sigma Co, St. Louis, MO) or 200 µL 0.9% saline (Hospira, Lake 
Forest, IL) by intraperitonal injection every 14 days for a 10 week treatment period (n=10; 5 
male & 5 female mice/ group).  In addition to cisplatin (6 µg/g body weight), two additional 
groups of animals received either a low dose (25 µg/g body weight) or a high dose (50 µg/g body 
weight) of LM11A-31 (courtesy Dr. Frank Longo, Stanford, CA) by intraperitoneal injection 
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every 24 hours for the 10 week treatment period (n=12; 6 male & 6 female mice/ group).  Mice 
were observed daily throughout the treatment for hair and weight loss.  All animal experiments 
and testing were approved by the East Carolina University Animal Care and Use Committee 
(AUP:174a, see Appendix A). 
 
C2.  Von Frey/ Semmes-Weinstein sensory threshold testing of hindpaw 
 All animals were subjected to Von Frey/Semmes-Weinstein monofilament sensory 
threshold testing of the hind paws as previously described (James et al., 2010) every two weeks 
for the 10 week treatment period.   Briefly, animals were placed within a clear plastic barrier 
upon an elevated screen and allowed to acclimate for 10 to 15 minutes. Von Frey/Semmes-
Weinstein monofilaments (Stoeling Co., Wood Dale, IL) were applied to the point of bending 
onto the plantar surface of left and right hindpaws. Monofilament testing proceeded from the 
smallest diameter until the applied monofilament elicited response.  Responses were recorded as 
positive when the animal responded 3 out of 5 applications.  Differences between treatment 
groups were determined by t-test analysis using SigmaPlot 10.0 (Systat Software Inc., San Jose,  
CA). 
 
C3.  Tissue preparation  
 Animals were deeply anesthetized with 3% isoflurane vapor and euthanized by cervical 
dislocation.  Tissues (dorsal root ganglion, sural and sciatic nerves) were rapidly removed and 
either fresh frozen on liquid nitrogen (for protein analysis) or fixed in Zamboni's fixative (2% 
paraformaldehyde, 0.5% picric acid, and 0.1% phosphate buffer) overnight.  Tissue samples 
were then washed with phosphate-buffered saline and cryoprotected overnight in 30% sucrose in 
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PBS at 4
o
C.  Tissues were then embedded in OCT and rapidly frozen with chilled isopentane. 
5µm thick cryostat sections were affixed to Superfrost slides (Fisher Scientific, Pittsburgh,  PA).   
 
C4.  Immunofluorescent analysis of peripheral nerve tissue 
 For immunostaining, sections were incubated with 0.2% Triton X-100 for 10 minutes at 
room temperature, 20 minutes at room temperature with 100mM glycine and blocked 30 minutes 
at 37 
o
C with 10% bovine serum albumin (BSA).  Primary antibodies (rabbit total RhoA 1:100, 
Santa Cruz Biotechnology, Santa Cruz, CA; rabbit phosphorylated RhoA 1:100, Santa Cruz 
Biotechnology, Santa Cruz, CA) were all incubated overnight at 4
o
C.  Immunofluorescent 
images were captured and analyzed with a Zeiss Axiovert S100 fluorescent light microscope 
(Carl Zeiss, Thornwood,  NY). n= 3 sural nerves/ treatment group.   
 
C5.  Morphological analysis of peripheral nerve tissue 
 Morphometric evaluation of phase contrast images of sural nerve cross sections, captured 
at 63X with a Zeiss Axiovert S100 fluorescent light microscope (Carl Zeiss, Thornwood, NY), 
were conducted using MetaMorph™ 4.6 imaging software systems (Molecular Devices, 
Sunnyvale, CA).  Due to natural size variation in sural nerves, morphometric analysis was 
carried out on three randomly selected 40 µm
2
 regions in each nerve and averaged to obtain data 
for each sural nerve evaluated.  Briefly, myelinated fiber (axon + myelin), axon, and myelin 
areas were measured with image analysis software.  Based on the total area of the region counted 
(1600 µm) percentages of space occupied by axons, myelin, and total fibers were calculated.  
Additionally, after subtracting the total fiber area from the total area of the region, the percentage 
of endoneural space that was unoccupied by myelinated nerve fibers was determined. t-test 
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analysis was performed using SigmaPlot 10.0 (Systat Software Inc., San Jose,  CA) to determine 
differences between drug treatment groups. n= 6 sural nerves/ treatment group. Any null 
hypothesis with the probability level less than 95 % was rejected. 
 
C6.  Protein analysis of peripheral nerve tissue 
 Due to the inability to obtain sufficient protein from sural nerves, flash frozen sciatic 
nerves were utilized for protein analysis.  Harvested sciatic nerves were frozen on liquid 
nitrogen, crushed, and homogenized in a buffer consisting of 50mM Tris pH 7.4, 50mM sodium 
chloride, 5 mM magnesium chloride, 1 mM dithiothreitol (DTT), and 1% Triton X-100, and 
supplemented with protease inhibitors (1mM phenylmethanesulfonylfluoride (PMSF), 10mM 
sodium pyrophosphate, 20mM sodium fluoride, 1mM sodium orthovanadate, and a protease 
inhibitor cocktail (Roche Applied Science, Indianapolis, IN)).  After determination of protein 
concentrations, equal amounts of protein were loaded onto an 18% tris-glycine gel (Invitrogen, 
Carlsbad, CA), transferred to PVDF membrane (Milipore, Billerica, MA) and subjected to 
Western blot analysis.  Blots were blocked and probed with mouse total RhoA 1:400 
(Cytoskeleton Inc., Denver, CO), rabbit phosphorylated RhoA 1:500 (Santa Cruz Biotechnology, 
Santa Cruz, CA), rabbit total SHP2 1:500 (Milipore, Billerica, MA), and phosphorylated SHP2 
(Y542) 1:500 (Cell Signaling Technology, Danvers, MA). GAPDH (mouse, 1:2000; 
Calbiochem, San Diego, CA) was used as a loading control.     
 
C7.  Primary neuronal cultures 
 Primary cortical neurons were isolated from a 18-day timed pregnant mouse as 
previously described (James et al., 2008).  Neurons were cultured for 5 days in vitro (DIV) in B-
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27 supplemented Neurobasal media (Invitrogen Carlsbad, CA) then selected neurons were 
treated for 24 hours with cisplatin (8 µg/mL).  LM11A-31 was then applied to selected neurons 
at 6 DIV at a concentration of 100 nM for an additional 24 hours.  Finally, at 7 DIV, selected 
cells were treated with calpeptin for 30 minutes (1 unit/mL; Cytoskeleton, Denver, CO).  
Neurons were then fixed for 15 minutes in 4% paraformaldehyde.  
 
C8.  Neuronal morphological analysis 
 Neuronal actin-based structures were identified with fluorescein-phalloidin (Molecular 
Probes, Eugene, OR) and nuclei were labeled with Hoechst.  Neuronal images were captured 
using a Zeiss Axiovert S100 (Carl Zeiss, Thomwood, NY).  Morphometric analyses were then 
performed  using MetaMorph™ 4.6 imaging software systems (Molecular Devices, Sunnyvale, 
CA) as previously described (James et al., 2008; Jones et al., 2004).  Briefly, branch numbers 
were determined by applying the MEASURE COUNT OBJECT function of the software system. 
Branches were scored when they were longer than 10 m. Processes shorter than 10 m were 
designated as sprouts, and not counted as branches.  The imaging system was calibrated so that 
dendrite length measurements were true values.  t-test  analysis was performed using SigmaPlot 
10.0 (Systat Software Inc., San Jose, CA) to determine differences between drug treatment 
groups. n= 3 representative neurons/ treatment group. Any null hypothesis with the probability 
level less than 95 % was rejected. 
 
C9.  Neuronal RhoA immunofluorescence  
 Primary cortical neurons on poly-L-lysine coated coverslips, treated as previously 
described, were incubated with 0.2%  Triton X-100 for 10 minutes at room temperature, 20 
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minutes at room temperature with 100mM glycine and blocked 30 minutes at 37 
o
C with 10% 
bovine serum albumin (BSA).  Primary antibodies (rabbit total RhoA 1:100 and rabbit 
phosphorylated RhoA 1:100, Santa Cruz Biotechnology, Santa Cruz, CA) were incubated one 
hour at room temperature.  Immunofluorescent images were captured and analyzed with a Zeiss 
Axiovert S100 fluorescent light microscope (Carl Zeiss, Thornwood, NY). n= 3 representative 
neurons/ treatment group.   
 
C10.  Analysis of protein expression in neuronal lysates 
 Mouse primary cortical neurons were treated as previously described, lysed with RIPA 
buffer  supplemented with protease inhibitors (1mM phenylmethanesulfonylfluoride (PMSF), 
10mM sodium pyrophosphate, 20mM sodium fluoride, 1mM sodium orthovanadate, and a 
protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN)), and subjected to Western 
blot analysis. Blots were blocked and probed with anti-phosphorylated RhoA 1:500 (Santa Cruz 
Biotechnology, Santa Cruz, CA) and  anti-rabbit phosphorylated SHP2 (Y542) 1:500 (Cell 
Signaling Technology, Danvers,  MA).  
 
C11.  Statistical analysis 
 t-test analysis was performed using SigmaPlot 10.0 (Systat Software Inc., San Jose, CA) 
and p-values were designated for each experiment, each of which were repeated a minimum of 
three times.  Any null hypothesis with probability level less than 95% was rejected. 
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D.  Results 
D1.  Cisplatin-induced decline in sensory function can be prevented with concurrent use of 
LM11A-31   
 CIPN was induced in age-matched C57/BL6 mice by intraperitoneal administration of 6 
µg/g body weight (18 mg/m
2
) cisplatin once every two weeks for a ten week treatment period (5 
successive doses).  Such doses are clinically relevant and represent a high, yet tolerable, dose 
successfully used to induce neuropathy in mice (James et al., 2010; Verdú et al., 1999).   In 
addition to cisplatin, two additional, selective groups of mice received either a high (50 µg/g) or 
low (25 µg/g) dose of the p75
NTR
 receptor ligand mimetic, LM11A-31.  This compound targets 
the p75
NTR
 receptor (Massa et al., 2006; Longo and Massa, 2008), which is known to lie 
upstream of RhoA activation and modulate Rho GTPase activity (James et al., 2008).  Saline-
treated mice were maintained as experimental controls.  Mice were observed daily for clinical 
signs of chemotherapy treatment such as hair and weight loss.  All mice receiving cisplatin 
showed consistent weight loss over the course of treatment, as well as increased hair loss.  Any 
mice displaying any signs of discomfort, pain, or weight loss exceeding 20% of original body 
weight were euthanized in accordance with the East Carolina University Animal Care and Use 
Committee guidelines for animal use. 
 In order to assess peripheral nerve function in both control and experimental groups, Von 
Frey/Semmes-Weinstein monofilament testing was performed as previously described (James et 
al., 2010; Ta et al., 2009).  Briefly, following a 10 minute acclimation period, Von 
Frey/Semmes-Weinstein monofilaments of varying diameters, which correspond to force, were 
sequentially applied to the plantar surface of the hindpaw until positive responses were elicited.  
Positive responses included both hindpaw withdrawal and licking and were recorded when 
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elicited at a specific force for 3 out of 5 monofilament applications.  Clinically, similar testing is 
frequently employed to screen patients with suspected diabetic or chemotherapy-induced 
peripheral neuropathies (Grisold et al., 2012; Feng et al., 2009).  In that case, the monofilaments 
are placed perpendicularly against the plantar surface of the great toe until bending, if a patient 
does not respond,  monofilaments in ascending order are applied until a sensation is felt 
(Tanenberg, 2009).  
 In the current experiment, touch perception analysis with Von Frey/Semmes-Weinstein 
monofilaments showed a significant increase (p= 0.04, relative to saline) in force required to 
elicit a response, indicative of a decline in sensory nerve function, in the cisplatin treated group 
after 6 weeks (Fig. 2.1).  However, addition of LM11A-31 at either high (50µg/g) or low 
(25µg/g) doses prevented these deficits in touch perception, as seen by significant reductions (p= 
0.02, relative to cisplatin) in force applied to the hindpaw.  Neither LM11A-31 doses alone 
showed responses that were significantly different from saline over the 10 week treatment 
period. 
 
D2.  LM11A-31 treatment reduces abnormal sural nerve fiber morphology induced by cisplatin 
 The rodent hindpaw, as well as the human foot, is innervated by branches of the sciatic 
nerve (tibial, common peroneal (fibular) and sural).  The predominately sensory sural nerve 
provides innervation to the lower hind leg, heel, and plantar surface of the hindpaw or heal in the 
human foot. Therefore, sural nerves were harvested post treatment, Zamboni fixed, frozen and 5 
µm cross-sections were subjected to further analysis.  Through phase contrast microscopy, which 
highlights the myelin sheath as dark ring-like structures surrounding the inner axon, differences 
in nerve fiber morphologies can be seen between control and cisplatin-treated groups.  As shown 
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in Fig. 2.2A, saline-treated nerve fibers display round morphologies that are well myelinated, as 
demonstrated by the dense black circles (red arrow).  However, abnormally shaped nerve fibers 
(yellow arrows) and decreases in the degree of myelination (red arrows) were frequently 
observed in cisplatin-treated nerves, which is consistent with our previous data (James et al., 
2010).  Addition of 50 µg/g LM11A-31 to cisplatin treatment alleviated myelin sheath reduction 
(red arrow) and fibers maintained a rounded fiber morphology closely resembling that of saline.  
Interestingly, nerve fibers that received a lower dose of LM11A-31 maintained a high degree of 
myelination but, like cisplatin fibers, anomalous flattened and infolded morphologies were 
consistently observed (yellow arrows). 
 Due to natural variation in nerve sizes between animals, randomly selected 40 um
2
 
regions of sural nerve cross sections were used to collect and quantify morphological data (Fig. 
2.2 B-F).  All sural nerve sections were derived proximal to the sciatic bifurcation and displayed 
a single fascicle. Comparisons between the percentage of the total area occupied by axons, 
myelin and total fiber (myelin plus axon; Fig. 2.2B, C and D, respectively) showed a reduction in 
cisplatin nerves which was prevented by addition of either dose of LM11A-31 (p=0.05).  
Additionally, a 10% increase in percentage of the total area not occupied by fibers observed in 
cisplatin nerves (p=0.05) was diminished with either LM11A-31 doses (p=0.05; Fig. 2.2 E). 
Importantly, quantification of nerve fibers treated concurrently with LM11A-31 and cisplatin 
were not significantly different from saline.  G-ratios, which describe the degree of myelination 
of a nerve fiber  as a ratio between axonal diameter/fiber diameter (Rushton, 1951), were also 
calculated.  Data revealed G-ratios within the optimal range (0.47-0.6) for the sural nerve in all 
four treatment groups (Chomiak and Hu, 2009; Fig. 2.2F).  Cisplatin treatment alone did not alter 
the G-ratio significantly from saline.  However, significant increases in the degree of myelination 
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were observed with both high and low LM11A-31 doses, further supporting data suggesting the 
p75
NTR
 receptor plays an important role in myelin regulation (Cosgaya et al., 2002; Song et al., 
2006). 
 
D3.  LM11A-31 inhibits cisplatin-induced increase in phosphorylated RhoA but promotes SHP2 
phosphorylation in peripheral nerves   
 To determine and compare RhoA activity levels between treatment groups we performed 
immunofluorescent analysis of frozen sural nerve cross sections with antibodies detecting total 
levels of RhoA (tRhoA) and phosphorylated RhoA (pRhoA).  Phosphorylation at serine 188 is an 
important site  for negative regulation of RhoA by cAMP and cGMP-dependent kinases (Dong et 
al., 1998; Ellerbroek et al., 2003; Sawada et al., 2001).  Therefore, decreases in pRhoA are 
indicative of an increase in the levels of active (GTP-bound) RhoA.   Immunofluorescent data 
revealed only a slight increase in tRhoA activity in cisplatin nerves compared to controls, while 
both doses of LM11A-31 showed an overall reduction in tRhoA activity (Fig. 2.3A, top panel).  
Quantification of pixel intensity in Fig. 3B confirms the visual comparison and demonstrates 
LM11A-31 not only significantly reduces tRhoA activity compared to cisplatin (p=0.05), but 
also  to saline (p=0.0001).  pRhoA immunostaining (Fig. 2.3A, bottom panel), on the other hand, 
reveals a dramatic 32% pRhoA decrease in cisplatin versus saline nerves (p=0.0001, Fig. 2.3C), 
suggesting an increase in active RhoA levels.  Addition of 50 µg/g LM11A-31 revealed a 40% 
pRhoA activity increase relative to cisplatin (p=0.0001) and closely resembled saline controls.  
However, the lower LM11A-31 dose was only minimally effective in preventing cisplatin-
induced pRhoA decreases with only a 2% increase in pixel intensity versus cisplatin only nerves 
(Fig. 2.3C). Interestingly, this data implies that tRhoA activity can be inhibited similarly 
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regardless of high or low dose, but LM11A-31 is less sensitive at lower doses for pRhoA activity 
inhibition. When expressed as a ratio of pRhoA to tRhoA the pixel intensity quantification more 
clearly describes the activity level of RhoA due to treatment (Fig. 2.3D). These data demonstrate 
a significant 40% increase in RhoA activity due to cisplatin which could be significantly 
inhibited by the addition of high (65%; p=0.0002) and low (37% p=0.04) LM11A-31 doses.  
Such results not only support our hypothesis that RhoA activity is increased due to cisplatin 
treatment, but suggest that treatment with LM11A-31 could be employed as a preventative 
measure. 
 In order to further confirm RhoA's role in CIPN we assessed protein expression in fresh 
frozen sciatic nerve samples.  Due to insufficient protein concentrations obtained from sural 
nerves, we utilized the larger sciatic nerve from which the sural nerve branches in the mouse. 
The tRhoA expression appeared to be unchanged in the sciatic nerve, regardless of treatment 
(Fig. 2.4, first panel).  However, reflecting pRhoA immunofluorescent results, cisplatin 
decreased pRhoA expression and concurrent use of LM11A-31 lead to expression similar to 
controls (Fig. 2.4, second panel). SHP2 tyrosine phosphatase, downstream of NGF receptor 
tyrosine kinases, is known to modulate RhoA signaling. Additional analysis of both 
phosphorylated (Fig. 2.4, third panel) and total SHP2 phosphatase (Fig. 2.4, fourth panel) levels 
were performed. Results demonstrated decreased expression of phosphorylated SHP2, which is 
correlated with increased RhoA activity, due to cisplatin treatment. LM11A-31 treatment was 
able to abrogate this effect when used in conjunction with cisplatin.  However, similarly to 
tRhoA levels (Fig. 2.4, first panel), total levels of SHP2 (Fig. 2.4, fourth panel) were not altered 
by either cisplatin or LM11A-31.   
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D4.  LM11A-31 and SHP2 phosphatase modulation can inhibit cisplatin-induced 
neurodegeneration   
 RhoA has been well established as a negative regulator of neuronal branching (Ahnert-
Hilger et al., 2004; Bito et al., 2000; Threadgill et al., 1997). In order to further analyze the 
effects of cisplatin and LM11A-31 on RhoA and RhoA-mediated processes in vitro, a primary 
neuronal culture system was established from E18 mouse cortical tissue.  Typical neuronal 
development begins with axonal extension at 3 days in vitro (DIV) and establishment of 
dendritic processes from 5-7 DIV (Dotti et al., 1988; James et al., 2008).  Therefore, cortical 
neurons were cultured for 5 DIV, treated with cisplatin (8 µg/mL), and after 24 hours, LM11A-
31 (100 nM) was then applied for an additional 24 hours. At 7 DIV, RhoA was constitutively 
activated in selected cells with a SHP2 phosphatase inhibitor, calpeptin, for 30 minutes (1 
unit/mL).  Tyrosine dephosphorylation of p190-B RhoGAP modulated by SHP2 phosphatase has 
been shown to function as a constitutive RhoA activator (Kontaridis et al., 2004; Sordella et al., 
2003). 
 As depicted in Fig. 2.5.A (upper panel) immunofluorescent analysis of actin-based 
structures reveals a distinct reduction in branching due to treatment with either calpeptin or 
cisplatin.  Quantification of branch number (Fig. 2.5B), sprout number (Fig. 2.5C), and branch 
length (Fig. 2.5D) shows significant reductions due to cisplatin treatment.  However, RhoA 
activation through SHP2 phosphatase resulted in less dramatic (not significant) reductions in 
both branch (Fig. 2.5B) and sprout (Fig. 2.5C) numbers.  In contrast, addition of LM11A-31 to 
cisplatin treatment increased branch numbers (Fig. 2.5B), sprout numbers (p<0.03; Fig. 2.5C), 
and branch length (p<0.02; Fig. 2.5D).  Concurrent treatment of LM11A-31 and calpeptin 
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resulted in a significant increase in branch number (p<0.05; Fig. 2.5B), while sprouting and 
branch length remained unchanged.   
 In order to elucidate RhoA activity in treated neurons, pRhoA immunostaining was 
performed.  Total RhoA levels (Fig. 2.6A; upper panel) were shown to be similar in cisplatin and 
control neurons, while calpeptin treatment significantly increased the total level of RhoA (Fig. 
2.6B; p<0.005).  Addition of LM11A-31 to both cisplatin and calpeptin-treated cells resulted in 
significant decreases in tRhoA activity compared to each treatment alone (Fig. 2.6B).  As shown 
in Fig. 2.6A (lower panel) and quantified and Fig. 2.6C, results revealed a significant increase in 
pRhoA activity due to both calpeptin (p<0.01) and cisplatin (p<0.0006) application relative to 
non-treated controls.  The addition of LM11A-31 significantly inhibited these increases elicited 
by cisplatin (p<0.003). The same inhibitory trend from LM11A-31 can be observed for these 
increases elicited by calpeptin, although the inhibition was not significant. The ratio of pRhoA to 
tRhoA pixel intensity revealed expected increases in RhoA activity in both calpeptin (p<0.0006) 
and cisplatin-treated (p< 0.002) neurons that was attenuated with addition of LM11A-31 to 
cisplatin-treated (p<0.009) neurons, but not those treated with calpeptin (Fig. 2.6D).  These 
results not only further support RhoA as a negative regulator of neurite branching, but confirm 
our in vivo results suggesting that LM11A-31-mediated RhoA inhibition can preserve neuronal 
structure during cisplatin treatment. 
 Additional analysis of protein expression in lysates prepared from primary neuronal 
cultures treated with cisplatin, calpeptin and LM11A-31 were performed. As depicted in Fig. 
2.6E decreases in pRhoA expression, indicative of increased levels of active RhoA, were 
observed in cisplatin-treated lysates which could be countered by LM11A-31 application. 
However, calpeptin treatment did not result in major reductions in pRhoA expression.  
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Additionally, co-treatment of neuronal cultures with LM11A-31 and calpeptin did not display 
clear inhibitory actions on protein expression levels. Phosphorylated SHP2 (pSHP2) expression, 
which is indicative of inhibited SHP2 phosphatase activity and increased RhoA activation, was 
shown to be significantly decreased due to both cisplatin (p<0.02) and calpeptin-treatment 
(p<0.03; Fig. 2.6F).  However, LM11A-31 was able to attenuate cisplatin-induced pSHP2 
reductions but not calpeptin. These results indicate that at the neuronal culture level there are 
likely two independent mechanisms of RhoA activations through p75
NTR
 and calpeptin-induced 
inhibition of SHP2 phosphatase. 
 
E.  Discussion 
 Peripheral neuropathy remains a debilitating, dose-limiting side effect of many platinum-
based chemotherapeutics. To date,  multiple avenues of neuroprotective intervention have been 
investigated with concurrent cisplatin use including Vitamin E (Pace et al., 2003; Pace et al., 
2007; Pace et al., 2010), glutathione (Cascinu et al., 1995; Smyth et al., 1997) and Org 2766,  an 
adrenocorticotrophic hormone analogue (Koeppen et al., 2004; van der Hoop et al., 1990a).  
However, clinical success has been minimal; leaving dose reductions or alterations in dose 
scheduling the only option for patients (Beijers et al., 2012; Pachman et al., 2011; Schloss et al., 
2013). 
 In the current study, we show elevation of the small GTPase RhoA is correlated with 
increased incidence of peripheral neuropathy in a mouse model of CIPN.  Additionally, upstream 
inhibition of RhoA with LM11A-31, a p75
NTR
 receptor ligand mimetic, could not only suppress 
RhoA upregulation in cisplatin-treated mice, but prevent cisplatin-induced decline in peripheral 
nerve function seen using the Von Frey/Semmes-Weinstein monofilament testing. Importantly, 
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morphological analysis of sural nerve cross sections revealed that abnormal nerve fibers 
frequently seen due to cisplatin treatment could be thwarted with the addition of LM11A-31 at 
both high and low doses. Our in vitro studies also support data derived in our in vivo model of 
CIPN. For example, the increased RhoA activity and dramatic reduction in neurite branching and 
sprouting due to cisplatin application could be inhibited by addition of LM11A-31.  Such results 
suggest a novel neuroprotective target that could be exploited during cisplatin chemotherapy. 
 p75
NTR
 receptor acts as a displacement factor that releases RhoA from Rho GDP-
dissociation inhibitor (Yamashita and Tohyama, 2003). This activation of RhoA has a key role in 
inducing inhibition of axon growth (Ahnert-Hilger et al., 2004; Kranenburg et al., 1997). Our 
studies support a model that in addition to its inhibitory action on DNA synthesis, cisplatin elicits 
cellular stress leading to p75
NTR
 receptor dissociation from RhoA, thereby promoting RhoA 
activation and signaling to Y-27632-sensitive p160
ROCK
/Rho kinase. Increased RhoA/ROCK 
signaling results in axon retraction and repulsion (Nakayama et al., 2000; Fig 2.7). Furthermore, 
cisplatin-induced cellular stress suppresses SHP2 tyrosine phosphatase, which also activates 
RhoA. Calpeptin-sensitive inhibition of SHP2 activates RhoA and attenuates neurite branching 
and extension, further supporting this model. Notably, cisplatin-induced increases in RhoA 
activity and decreases in tyrosine phosphorylation of SHP2 can be reversed by LM11A-31 
treatment. LM11A-31 also countered the trends of calpeptin in activating RhoA and reducing 
neuronal sprout numbers. Therefore, LM11A-31 is a small molecule that can effectively reduce 
the impact of experimental CIPN. 
 Identification of RhoA signaling as a potential neuroproetctive target in CIPN has 
important implications. Studies showed that inhibition of RhoA downstream effector 
p160
ROCK
/Rho kinase by Y-27632 attenuated tumor growth, indicating that suppression of RhoA 
 67 
 
signaling may be used as an adjuvant to counteract negative side effectst of cisplatin 
chemotherapy (Routhier et al., 2010). Employment of RhoA inhibitor in the treatment regimen 
may also allow cisplatin to be effective at the lower dosages, further reducing the risks of 
peripheral neuropathy. The identification of the RhoA upstream modulator p75
NTR
 and its 
inhibitor LM11A-31 provided yet additional important evidence that RhoA suppression is a 
potential site of intervention to circumvent CIPN. Interestingly, the nerve growth factor (NGF) 
receptor has also been implicated in cisplatin-induced neurotoxicity, and as shown by Aloe et al. 
(2000) that repeated administration of exogenous NGF can be an effective measure to combat 
cisplatin damage in the mouse (Authier et al., 2009).  Future studies will determine the 
neuroprotective effects of LM11A-31 in tumor-bearing mouse models as a significant step 
towards its application  clinically.  
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Figure 2.1  Cisplatin-induced decline in sensory function can be prevented with concurrent 
use of LM11A-31.  
 Peripheral nerve function was analyzed by mechanical (touch) stimulus perception using Von 
Frey/ Semmes-Weinstein monofilaments. Results showed that cisplatin induced a decrease in 
sensory function over the course of treatment that could be prevented by either high or low doses 
of LM11A-31.  Values represent mean ± S.E.M.  p< 0.04 *, relative to saline;  p<0.02 
Δ 
, relative 
to cisplatin.  n= 10 animals/ treatment group saline and cisplatin; n=12 animals/ treatment group 
LM11A-31 high and low dose. 
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Figure 2.2 LM11A-31 treatment reduces abnormal sural nerve fiber morphology induced by 
cisplatin.  
Sural nerve cross sections were analyzed by phase-contrast microscopy (63X).  (A) Cisplatin 
altered sural nerve morphology (yellow arrows) and myelination (red arrows) in comparison to 
saline treatment. LM11A-31 treatment reversed the cisplatin-induced abnormally shaped nerve 
and reduced myelination. Quantification of sural nerve axon (B), myelin (C), fibers (axon + 
myelin, D), unoccupied (E) percent of areas in randomly selected 40 um
2
 regions, and G-ratio 
(ratio of axonal diameter to the total fiber diameter which then reflects the level of myelination 
of a nerve fiber, F) of sural nerve cross sections.  Results indicate a reduction in the percent of 
area occupied by axons (B), myelin (C) and fibers (D) in the cisplatin treated group and a 
significant recovery with LM11A-31 treatment.  Additionally, the percent of space unoccupied 
by nerve fibers (E) was significantly increased in cisplatin treated sural nerves, which could be 
prevented by addition of LM11A-31. G-ratio (F) calculations revealed the degree of myelination 
is significantly increased with addition of LM11A-31 relative to cisplatin. Values represent mean 
± S.E.M.  p< 0.05 **, relative to saline; p<0.05 *, relative to cisplatin. n=6 regions/ treatment 
group. 
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Figure 2.3 LM11A-31 inhibits cisplatin-induced increase in phosphorylated RhoA in the sural 
nerve.   
Total RhoA (tRhoA) and phosphorylated RhoA (pRhoA) immunofluorescent analysis of 5 um 
sural nerve cross sections. (A, lower panel) Results revealed an increase in the levels of active 
RhoA due to cisplatin treatment as indicated by a decrease in pRhoA immunostaining.  However, 
cisplatin treatment did not alter the expression of total RhoA levels (A, upper panel).   
Concurrent treatment with LM11A-31 showed an increase in pRhoA and a decrease in tRhoA 
immunostaining which is indicative of RhoA inhibition. Quantification of pixel intensity of 
tRhoA (B), pRhoA (C) and the ratio of pRhoA pixel intensity to tRhoA pixel intensity  (D) were 
determined.  Values represent mean ± S.E.M; *, relative to saline; Δ, relative to cisplatin. n=4 
nerves/ treatment group. 
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Figure 2.4 Increased pRhoA and pSHP2 protein expression due to cisplatin treatment can be 
inhibited by a high dose of LM11A-31.   
Mouse sciatic nerves were harvested, homogenized and subjected to Western blot analysis.   
Blots were then probed with total RhoA (tRhoA), phosphorylated RhoA (pRhoA), 
phosphorylated SHP2 (pSHP2), and total SHP2 (tSHP2) antibodies.  GAPDH was used as a 
loading control.     
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Figure 2.5 LM11A-31 inhibits cisplatin-induced neurodegeneration. 
 Mouse cortical neurons grown for 5 days in vitro (DIV) were treated for 24 hours with cisplatin 
(8 ug/µL), at 6 DIV with LM11A-31 for 24 hours (100nM), or at 7 DIV with calpeptin for 30 
minutes (1 unit/mL).  (A) Neurons were labeled with FITC-phalloidin (green); nuclei were 
labeled with Hoechst (inset, blue). Quantification of branch number (B), sprout number (C), 
branch length (D) and pRhoA pixel intensity (E).  Values represent mean ± S.E.M. *, relative to 
saline; Δ, relative to cisplatin; Φ, relative to calpeptin. n= 3 representative neurons/ treatment 
group.  
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Figure 2.6 LM11A-31 inhibits RhoA activity stimulated by cisplatin and calpeptin.  
Mouse cortical neurons grown for 5 days in vitro (DIV) were treated for 24 hours with cisplatin 
(8 ug/mL), at 6 DIV with LM11A-31 for 24 hours (100nM), or at 7 DIV with calpeptin for 30 
minutes (1 unit/mL).  (A) Neurons were labeled with total RhoA (top panel) and phosphorylated 
RhoA (lower panel).  Quantification of total RhoA pixel intensity (B), phosphorylated RhoA 
pixel intensity (C) and a ratio of the pixel intensity of phosphorylated RhoA to that of total 
RhoA(D) were calculated. n=3 representative neurons/ treatment group.   Western blot analysis 
of phosphorylated RhoA (E) and phosphorylated SHP2 (F) were also performed and quantified.   
Values represent mean ± S.E.M. *, relative to saline; Δ, relative to cisplatin; Φ, relative to 
calpeptin. 
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Figure 2.7 Proposed mechanism of cisplatin-induced peripheral neuropathy.   
Cisplatin-induced cellular stress (DNA and/or mitochondrial)  may result in the activation of 
both  the p75
NTR 
 receptor and SHP2 tyrosine phosphatase, through which RhoA can be 
activated, and resulting in neuronal retraction and repulsion can result. 
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CHAPTER III: SMALL MOLECULE TARGETING CDC42-INTERSECTIN 
INTERACTION DISRUPTS GOLGI ORGANIZATION AND SUPPRESSES CELL 
MOTILITY 
 
This chapter is modified and reprinted from the Proceeding of the National Academy of Science, 
110, 1261-1266 (2013), see Appendix B. 
 
A.  Summary 
 
Signaling through the Rho family of small GTPases has been intensely investigated for 
its crucial roles in a wide variety of human diseases. While RhoA and Rac1 signaling pathways 
are frequently exploited with the aid of effective small molecule modulators, studies on the 
Cdc42 subclass lagged due to lack of specific activator or inhibitors.  In order to solve this 
problem and fill this important gap, we have applied high-throughput in silico screening and 
identified compounds that are able to fit into the surface groove of Cdc42, which is critical for 
guanine nucleotide exchange factor (GEF) binding. Based on the interaction between Cdc42 and 
intersectin, a specific Cdc42 GEF, we discovered compounds that rendered intersectin-like 
interactions in the binding pocket. By using in vitro binding and imaging as well as biochemical 
and cell-based assays, we demonstrated that ZCL278 has emerged as a selective Cdc42-small 
molecule modulator that directly binds to Cdc42 and inhibits its functions. In Swiss 3T3 
fibroblast cultures ZCL278 abolished microspike formation and disrupted GM130-docked Golgi 
structures, two of the most prominent Cdc42-mediated subcellular events. ZCL278 reduces the 
peri-nuclear accumulation of active Cdc42 in contrast to NSC23766, a selective Rac inhibitor. 
ZCL278 suppresses Cdc42-mediated neuronal branching and growth cone dynamics as well as 
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actin-based motility and migration in a metastatic prostate cancer cell line (PC-3) without 
disrupting cell viability. Thus, ZCL278 is the first small molecule that specifically targets 
Cdc42-intersectin interaction and inhibits Cdc42-mediated cellular processes, therefore 
providing a powerful tool for research of Cdc42 subclass of Rho GTPases in human pathogenesis 
such as cancer and neurological disorders. 
 
B.  Introduction 
 Cdc42, a member of the Rho GTPase family of low molecular weight G-proteins, is an 
important regulator of many biological processes.  First identified by its involvement in the 
establishment of polarity in Saccharomyces cerevisiae, Cdc42 has since been shown to play key 
roles in cytoskeletal organization, vesicular trafficking, cell cycle control, and transcription 
(Cerione, 2004; Johnson and Pringle, 1990; Stengel and Zheng, 2011).  As with most GTPases, 
transduction of signals occurs through the exchange of GDP for GTP, thus activating Cdc42 
(Sinha and Yang, 2008). The cycling between nucleotide-dependent conformation states of Rho 
family GTPases is supported by three regulatory proteins:  guanine nucleotide exchange factors 
(GEFs), GTPase activation proteins (GAPs), and guanine nucleotide dissociation inhibitors 
(GDIs).  GEFs facilitate activation of the GTPase by catalyzing the exchange of bound GDP for 
GTP, while GAPs promote the GDP-bound confirmation (Lu et al., 2009; Ridley, 2006). 
Additional negative regulation occurs through GDIs which sequester Rho proteins in the 
cytoplasm and prevent nucleotide exchange (Ellenbroek and Collard, 2007). 
Recent studies have implicated aberrant Cdc42 activity in a variety of human pathologies 
including cancer and neurodegeneration (Auer et al., 2011; Stengel and Zheng, 2001). 
Interestingly, no mutations in the Cdc42 gene have been identified that can be attributed to 
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human cancer (Rihet et al., 2001). Abnormal phenotypes appear to be due to deregulation or 
overexpression of Cdc42 in an apparent tissue and microenvironment-dependent fashion (Stengel 
and Zheng, 2001). Cdc42 has been attributed to several aspects of cancer including cellular 
transformation (Lin et al., 1999) and metastasis (Chen et al., 2010; Johnson et al., 2010).  As a 
key regulator of neurite morphogenesis, Cdc42 has also been shown to be crucial for normal 
brain development, as conditional Cdc42 knockout mice do not survive birth and show gross 
brain abnormalities (Auer et al., 2011; Garvalov et al., 2007).  
However, among the three classical Rho subfamilies, studies on Cdc42 signaling lag 
behind those of RhoA and Rac1. This is partly due to the more rapid activation-inactivation 
cycles of Cdc42 in T-cells and the lack of selective small molecule tools to aid in capturing this 
process directly. In the current study, we have utilized computer-assisted virtual screening to 
identify compounds that are able to fit into the surface groove of Cdc42, which is critical for 
GEF binding.  Based on Cdc42’s interaction with intersectin (ITSN), a specific Cdc42 GEF, 
chemical compounds that rendered ITSN-like interactions in the binding pocket were 
preferentially selected for further investigation (Ahmad and Lim, 2010; Goreshnik and Maly, 
2010; Snyder et al., 2002).  We have now determined ZCL278 as a potent, cell permeable 
Cdc42-specific small molecule inhibitor that suppresses actin-based cellular functions, including 
Golgi organization and cell motility. 
 
C.  Experimental procedures 
C1.  Virtual screening  
 The Glide program (Schrodinger, New York, NY) was employed to screen the SPECS 
database consisting of 197,000 compounds for small molecules that can disrupt the interaction of 
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Cdc42 with ITSN. The crystal structure of Cdc42-ITSN complex (Protein Data Bank ID: 1KI1) 
(Synder et al., 2002) was used in the virtual screening. The ITSN residues that occupy the Cdc42 
binding interface are Leu1376, Met1379, Gln1380, Thr1383, and Arg1384. The binding pocket 
on Cdc42 was created with residues of Cdc42 within 7.0 Å of the center of the above five ITSN 
residues. After the protein structure was prepared in Protein Preparation Wizard, the docking 
grid was generated in the Receptor Grid Generation module. After preparation in LigPrep 
(Schrodinger, New York, NY), the compounds were subjected to HTVS (high-throughput virtual 
screening) docking and the top ranked 50,000 molecules were subjected to more stringent SP 
(standard precision) docking. The top ranked 100 molecules were manually inspected to select 
30 compounds for in vitro and biological testing.  
 
C2.  Compound synthesis 
General procedures  
 NMR spectra were recorded on a Bruker Avance III at 400 MHz. Chemical shifts are 
expressed in parts per million (™) relative to residual solvent as an internal reference (CDCl3: 
7.26; MeOD: 3.31; DMSO-d6: 2.50). High resolution mass spectra were obtained on Bruker 
micrOTOF II. Column chromatography was performed using Huanghai silica gel (45-75 μM). 
High performance liquid chromatography analysis was performed on an Agilent 1200 with a 
flow rate of 1 mL/min and a gradient of 20% v/v MeOH in H2O (t = 0.0 min) to 100% MeOH (t 
= 20.0 min) using a DAD detector. A ZORBAX Eclipse XDB-C18 column (4.6 mm×150 mm, 5 
μM) was used. Purity of compounds was based on the integrated UV chromatogram at 254 nm. 
All reagents and building blocks were commercially available unless otherwise indicated. 
Reactions were not optimized for maximum yields. 
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C3.  Synthetic procedures 
Ethyl 2-(4-bromo-2-chlorophenoxy) acetate (compound 2)  
 To a solution of 4-bromo-2- chlorophenol (solution 1) (5.2 g, 25.0 mM) and ethyl 2-
bromoacetate (4.3 g, 25.7 mM) in 50 mL DMF, anhydrous K2CO3 (3.45 g, 25.0 mM) was added 
(Fig. 3.1D). After stirring overnight at 70 
o
C, the mixture was poured into 150 mL water and 
extracted with ethyl acetate (70 mL×4). The organic layer was combined, washed with brine 
(100 mL ×3) and dried over anhydrous Na2SO4. The residue after rotary evaporation was 
purified by column chromatography to give compound 2 (6.18 g, 84.1% yield) as a light oil. 
1
H 
NMR (400 MHz, CDCl3): ™7.53 (singlet (s), 1H), 7.30 (doublet (d), 1H, J = 8.4 Hz), 6.72 (d, 
1H, J = 8.4 Hz), 4.68 (s, 2H), 4.26 (quartet (q), 2H, J = 7.2 Hz) and 1.29 (triplet (t), 3H, J = 7.2 
Hz). 
 
2-(4-Bromo-2-chlorophenoxy) acetic acid (compound 3) 
 To solution of 2 (5.0 g, 17.0 mM) in 50 mL dioxane, 1 M NaOH (50 mL) was added. 
After stirring at room temperature overnight, the mixture was acidified with 1 M hydrochloric 
acid to pH = 3. After the reaction mixture was extracted with ethyl acetate (50 mL×4), the 
organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated to 
give compound 3 (4.69 g, 94.3% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6): ™7.66 
(s, 1H), 7.44 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 8.8 Hz), 4.72 (s, 2H). 
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4-(3-(2-(4-Bromo-2-chloro-phenoxy)-acetyl)-thioureido)-N-(4,6-dimethyl-pyrimidin- 
2-yl)-benzenesulfonamide (compound 5) 
 Compound 3 (539 mg, 2.0 mM) in 25 mL SOCl2 and a drop of DMF were heated to 
reflux. After 3 hours, SOCl2 was removed by distillation and the residue was dried in vacuo for 5 
minutes to give crude acyl chloride compound 4. The solution of 4 in 10 mL dry acetone was 
added dropwise into sodium thiocyanate (326.8 mg, 4.0 µM) in 10 mL acetone at 0 
o
C. The 
mixture was stirred at 30 
o
C for 2 hours before 4-amino-N-(4,6-dimethyl-2- pyrimidinyl) 
benzenesulfonamide (556 mg, 2.0 mM) was added at 0 
o
C. After stirring at room temperature 
overnight, it was filtered and washed with water and acetone to give compound 5 (276 mg, 
23.6% yield) as a yellow powder. 
1
H NMR (400 MHz, DMSO-d6): 
™12.19 (s, 1H), 11.68 (s, 1H), 11.52 (br s, 1H), 7.99 (d, 2H, J = 8.4 Hz), 7.86 ( d, 2H, J = 8.4 
Hz), 7.70 (d, 1H, J = 1.6 Hz), 7.49 (d, 1H, J = 8.8 Hz), 7.10 (doublet doublet (dd), 1H, J1 = 8.8 
Hz, J2 = 1.6 Hz), 6.75 (s, 1H), 5.02 (s, 2H), 2.25 (s, 6H). HRMS (ESI): [M+Na]+3 
C21H19BrClN5NaO4S2 calculated 605.9648, found 605.9632. HPLC: purity 95.9% (t = 18.4 min). 
 
C4.  Fluorescence titration  
 Lyophilized Cdc42 protein (Cytoskeleton Inc., Denver, CO) was reconstituted to 5 
mg/mL in a buffer consisting of 50 mM Tris, 0.5 mM MgCl2, 50 mM NaCl, 3% sucrose, and 
0.6% dextran. The stock solution was then diluted to 1 μM in 5 mM phosphate buffer pH 7.4. 
Into a quartz cuvette containing Cdc42 solution, aliquots of ZCL278 were added and incubated 
for 5 minutes before each fluorescent measurement (Varian Cary Eclipse). The excitation 
wavelength was 275 nm and the fluorescence of tryptophan at 350 nm was measured after each 
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addition. The titration curve was fitted using the equimolar specific binding model in GraphPad 
and the Kd was calculated. 
 
C5.  Surface plasmon resonance  
 SPR experiments were performed on a Biacore T100 using CM5. All solutions used in 
the experiment were prepared with Milli-Q water, filtered with a 0.22 µm membrane filter, and 
degassed before use. Cdc42 solution in PBS (5 mM, pH 7.4) at a concentration of 1 mg/mL was 
diluted to 30 µg/mL with sodium acetate buffer (pH 4.0). The chip was activated with EDC/NHS 
(10 µL/min for 600 s). Then Cdc42 was loaded (5 µL/min for 400 s) and immobilized 
covalently. Roughly, 6000 RU of Cdc42 was immobilized on the chip. Any excess of unbound 
Cdc42 was removed by flowing PBS (5 mM, pH 7.4, with 2% DMSO) over the chip. ZCL278 
was prepared as 2.5-30 µM solutions in PBS (5 mM, pH 7.4, with 2% DMSO), and injected (10 
µL/min for 100 s). After each loading, data was collected and analyzed with the Biocore3000 
software and GraphPad. 
 
C6.  Determination of pKa values of ZCL278  
 A Gemini Profiler was used for pKa measurement. First, 0.607 mg of ZCL278 was 
dissolved in 8 mL water (with 15 M KCl and DMSO). The solution was titrated with 0.5 M HCl 
in the pH range of 3.0 to 11.0, and the response was recorded. The measurement was repeated 
with different concentrations of DMSO (60, 49.2, 41.1, 31.8 wt%) and the collected pKa values 
were plotted and extrapolated to 0 wt% DMSO to give the pKa values of ZCL278 in water: 3.48 
± 0.04, 6.61 ± 0.02, 7.45 ± 0.01. There are four nitrogen atoms that are potentially associated 
with the apparent pKa values: pyrimidine N (Na), sulfonamide N (Nb), aryl side of thioureido N 
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(Nc), and carbonyl side of thioureido N (Nd). The Na, corresponding to a pKa of 3.48, should be 
deprotonated and stay in a neutral form at the pH of 7.4. The NH groups with pKa values of 6.61 
and 7.45 should be partially deprotonated and give a population of charged species in solution. 
 
C7.  Measurement of the solubility of ZCL278  
 First, the standard linear plot was obtained by measuring the UV absorption (315 nm) of 
ZCL278 at the concentrations of 20, 30, 40, 50, 65 µM. A linear equation of y = 0.0119x + 
0.0101 was obtained. Next, excess amount of ZCL278 powder was dissolved in 10 µL DMSO, 
then dispersed into 3 mL PBS buffer (pH 7.4). More ZCL278 powder was added to ensure the 
solution reached complete saturation. The solution was sonicated, kept at room temperature for 5 
min, and filtered through 0.22 µm membrane to obtain the saturated solution A for measurement. 
At the same time, 10 µL of DMSO in 3 mL PBS was prepared as the blank control. Solution A 
was diluted by 5 times to give solution B. The UV absorption of solution B was measured and 
fitted into the linear equation to give a concentration of 36.24 µM (R2 = 0.9995). Thus the 
concentration of solution A of 181.18 µM was obtained as the solubility of ZCL278. 
 
C8.  p50RhoGAP or Cdc42GAP assay 
 Inorganic phosphate produced as a result of GTPase activity was measured using a 
p50RhoGAP or Cdc42GAP assay (Cytoskeleton Inc., Denver, CO), an absorbance-based 
detection method (Moskwa, et al., 2005). Briefly, Cdc42 was preloaded with either GTP or 
ZCL278 and incubated in the reaction buffer (provided in kit) for 20 minutes at 37°C.  GAP was 
then added for an additional 20 minutes at 37°C.  Following a 10-minute incubation in CytoPhos 
Reagent (Cytoskeleton Inc., Denver, CO) inorganic phosphate was detected at 650 nm. n=3 
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independent experiments/ treatment group.  Any null hypothesis with the probability level less 
than 95 % was rejected. 
 
C9.  Immunofluorescence  
 Serum starved Swiss 3T3 fibroblasts treated with or without Cdc42 activator (CN02, 
Cytoskeleton, Inc. Denver, CO), RhoA activator (CN01, Cytoskeleton, Inc. Denver, CO) , Rac 
activator (CN02, Cytoskeleton, Inc. Denver, CO), ZCL series compounds, Y-27632 (ROCK 
inhibitor; Tocris Bioscience, Bristol, UK) or NSC23766 (Rac1 inhibitor; Tocris Bioscience, 
Bristol, UK) were fixed in paraformaldehyde and subjected to immunostaining. For labeling of 
active Cdc42 and phosphorylated RhoA, cells were probed with mouse monoclonal antibody 
against an active Cdc42 (NewEast Biosciences, Malvern, PA) or rabbit anti-phosphorylated 
RhoA (Santa Cruz Biotechnology, Santa Cruz, CA). For GM130 immunofluorescent staining, 
cells were probed with mouse monoclonal antibody against GM130 (BD Biosciences, Franklin 
Lake, NJ). After appropriate secondary antibody labeling, rhodamine- or FITC-phalloidin 
(Molecular Probes, Eugene OR) were applied to stain filamentous actin. Immunofluorescent 
images were then analyzed using a Zeiss Axiovert S100 (Carl Zeiss, Thornwood, NY). Pixel 
intensity was measured at five random points of five cells and averaged to generate average pixel 
intensity for each treatment group using MetaMorph™ 4.6 imaging software systems (Molecular 
Devices, Sunnyvale, CA). Details of active Cdc42 immunostaining were demonstrated by 
presenting each image in the pseudocolor setting with MetaMorph software. 
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C10.  Western Blot 
  Serum starved PC-3 cells were treated with or without Cdc42 activator or  ZCL278 and 
lysed in a buffer containing 50mM Tris pH 7.5, 10mM MgCl2, 0.5M NaCl, and 1% Triton X-100 
plus a protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN). Western blotting 
were performed with a phospho-Rac1/cdc42 (Ser71) antibody (Milipore, Billerica, MA), a 
phospho-WASP antibody (Assay Biotech, Sunnyvale, CA) or GAPDH (Calbiochem, San Diego, 
CA), followed by secondary antibodies conjugated to horseradish peroxidase. The membrane 
was then developed by chemiluminesence (Amersham, Buckinghamshire, UK). 
 
C.11  G-LISA® 
 G-LISA® Cdc42 Activation Assay Kit (Cytokeleton Inc., Denver, CO) was used to 
measure Cdc42 activity.  Serum starved Swiss 3T3 cells were treated with or without the Cdc42 
activator, ZCL278 or NSC23766.  Cell lysates were then processed according to the 
manufacturer's protocol using 0.15 mg/mL total protein/sample.  Positive controls included cells 
activated with the Cdc42 activator and with a constitutively active Cdc42 protein (Cytoskeleton 
Inc., Denver, CO), while negative controls included untreated cells lysates and buffer-only 
controls.  Samples were developed using a colorimetric substrate (Cytoskeleton Inc., Denver, 
CO) and the absorbance was read at 490 nm (Biotek, Winooski, VT). n=3 independent 
experiments/ treatment group.  Any null hypothesis with the probability level less than 95 % was 
rejected. 
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C.12  Wound Healing Assay 
  Serum starved PC-3 cell monolayers were scratched at three distinct sites per well. Cells 
were then treated with or without the Cdc42 activator, ZCL278, or NSC23766.  Phase contrast 
images were obtained at 0 and 24 hours of treatment using a Zeiss Axiovert S100 (Carl Zeiss, 
Thomwood, NY).  The distance of migration was determined by measurement of the leading 
edge of the migrating cells using MetaMorph™ 4.6 imaging software systems (Molecular 
Devices, Sunnyvale, CA). To determine cell viability, PC-3 cells were incubated for 24 hours 
with or without the Cdc42 activator, ZCL278 or NSC23766.  Using the trypan blue dye 
exclusion method, the numbers of live and dead cells were obtained using the Countess 
Automated Cell Counter (Invitrogen, Carlsbad, CA). The p values were assigned in each 
experiment. n= 5 independent experiments/ treatment group.  Any null hypothesis with the 
probability level <95% was rejected. 
 
C13.  Primary neurons and time-lapse imaging 
 One-day old mouse pups were euthanized, and the brains were removed according to the 
animal use protocol approved by the East Carolina University Animal Use Committee. 
Dissociated neurons cultured on poly-L-lysine coated coverslips were treated at five days in vitro 
with DMSO (control) or ZCL278. Neurons were then fixed and stained with fluorescein-
phalloidin to reveal actin-based structures. Neuronal morphology was observed using a Zeiss 
Axiovert S100 immunofluorescent microscope (Carl Zeiss, Thomwood, NY) and branch 
numbers were analyzed with MetaMorph™ 4.6 imaging software systems (Molecular Devices, 
Sunnyvale, CA).  Results were averaged from 3 independent experiments (n=3/group). Any null 
hypothesis with the probability level <95% was rejected. 
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To determine growth cone dynamics, we applied time-lapse light microscopy according 
to a procedure described earlier (Jones et al., 2002; Jones et al., 2004).  Briefly, neurons grown at 
5 days in vitro were incubated with DMSO or ZCL278 and recorded for 10 minutes on 25 mm 
coverslips that were placed in an Attofluor cell chamber (Atto Instruments, Rockville, MD) on 
the heated stage of a Zeiss Axiovert S100 microscope (Carl Zeiss, Thomwood, NY). Differential 
interference contrast (DIC) images at 63X were captured by using a Hamamatsu Orca digital 
camera (Bridgewater, NJ). To minimize phototoxicity for the living cells, we used a computer-
driven automatic shutter to achieve minimum illumination (300 msec/frame). 
Filopodia/microspike dynamics within growth cones of recorded images were then studied using 
MetaMorph™ 4.6 imaging software systems (Molecular Devices, Sunnyvale, CA). 
 
C14.  Statistical analysis 
 t-test analysis was performed using SigmaPlot 10.0 (Systat Software Inc., San Jose 
California) and p-values were designated for each experiment, each of which were repeated a 
minimum of three times.  Any null hypothesis with probability level less than 95% was rejected. 
 
D.  Results 
D1.  Virtual screening for Cdc42 inhibitors  
 Analysis of the three-dimensional structure of Cdc42-ITSN complex (Protein Data Bank: 
1KI1) revealed a main binding region between Cdc42 and ITSN (Synder et al., 2002). Residues 
Gln1380 and Arg1384 of ITSN were observed to form hydrogen bonds with Asn39 and Phe37 of 
Cdc42, respectively. Two clusters of hydrophobic interactions were found between Leu1376, 
Met1379 and Thr1383 of ITSN and Phe56, Tyr64, Leu67 and Leu70 of Cdc42. To screen for 
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Cdc42 inhibitors, the putative binding pocket on Cdc42 was created within 7 Å of the center of 
the above ITSN residues that interact with Cdc42. The binding pocket consists of 16 Cdc42 
residues including Thr35, Val36, Asn39, Phe56 and Asp57 (Fig. 3.1A). The 197,000 compounds 
from SPECS were screened using HTVS (high-throughput virtual screening) and SP (standard 
precision) docking sequentially. The top ranked 100 molecules were subjected to manual 
inspection according to the following criteria: ITSN-like binding posture and occupation for the 
Leu1376, Gln1380, Arg1384, Met1379 and Thr1383 residue space of ITSN should be observed; 
at least three hydrogen bonds should be formed; a conserved hydrogen bond with Asn39 or 
Phe37 of Cdc42 should exist; diversity of scaffolds should be considered. A selection of 30 
compounds was eventually tested for their ability to disrupt against Cdc42 activity and/or 
functions.  
 
D2.  Computed binding mode of ZCL278 in Cdc42  
 As shown in Fig. 3.1A, one small molecule, termed ZCL278, bound to a well-formed 
Cdc42 pocket lined by residues Thr35, Val36, Asp38, Asn39, Phe56, Tyr64, Leu67 and Leu70. 
Extensive favorable interactions were found between ZCL278 and Cdc42 residues. Five 
hydrogen bonds involving residues Thr35, Asn39 and Asp57, as well as hydrophobic interactions 
associated with residues Val36 and Phe56 were observed (Fig. 3.1B). The bromophenyl ring was 
inserted into the adjacent GTP/GDP binding pocket. The computed binding mode suggests that 
ZCL278 should be able to disrupt the Cdc42-ITSN interaction as well as GTP/GDP binding (Fig. 
3.1C). Indeed, the competition between GTP and ZCL278 to influence Cdc42 GTPase activity 
was confirmed by using p50RhoGAP or Cdc42GAP assay (Fig. 3.2). Our results suggest that 
increasing GTP addition can compete with preloaded ZCL278 on Cdc42 and increase GTP 
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hydrolysis by purified recombinant Cdc42 protein in vitro. Thus, local GTP/GDP should have 
impact on the effective doses of ZCL278 in the cells.  
 
D3.  Synthesis of Cdc42 inhibitor ZCL278 
 In order to confirm the screening hits and provide high purity samples for biological 
exploitation, ZCL278 was synthesized, purified, and characterized. As illustrated in a scheme 
(Fig. 3.1D), after compound 2 was prepared from 4-bromo-2-chlorophenol and ethyl 2-
bromoacetate in the presence of potassium carbonate, it was hydrolyzed in the alkali condition to 
provide acid 3. Treatment of compound 3 with refluxing thionyl chloride with DMF as a catalyst 
gave acyl chloride 4, which was converted to 4-(3-(2-(4-Bromo-2-chloro-phenoxy)-acetyl)-
thioureido)-N-(4,6-dimethyl-pyrimidin-2-yl)-benzene-sulfonamide (compound 5, ZCL278) after 
treatment with sodium thiocyanate, followed by reaction with 4-amino-N-(4,6-
dimethylpyrimidin-2-yl)-benzene-sulfonamide. 
 
D4.  Direct binding of ZCL278 and Cdc42 demonstrated by fluorescence titration and surface 
plasmon resonance 
 We assessed the binding affinity of ZCL278 and Cdc42 using two independent 
biophysical methods. First, fluorescence titration of purified Cdc42 by ZCL278 was carried out 
by monitoring the change of fluorescence intensity of a tryptophan residue on Cdc42 upon 
ZCL278 binding. Since ZCL278 has a weak absorption peak at 310 nm, in order to avoid any 
experimental error that might result from potential fluorescence quenching by ZCL278, the 
fluorescence emission of Cdc42 was monitored at 350 nm where ZCL278 has a negligible 
absorption. Thus, a Kd value of 6.4 M was obtained as the binding affinity of ZCL278 for 
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Cdc42 (Fig. 3.3A). To further demonstrate the direct interaction between ZCL278 and Cdc42, a 
surface plasmon resonance (SPR) experiment was performed by covalently immobilizing 
purified Cdc42 on a CM5 chip and varying ZCL278 concentration. The SPR response was 
observed to increase along with elevated ZCL278 concentrations and eventually gave a Kd of 
11.4 M (Fig 3.3B and C). Discrepancies in Kd values obtained by fluorescent titration (Fig. 
3.3A) and SPR experiments (Fig. 3.3B and C) can best be explained by decreased ZCL278 
solubility in the titration buffer, whereas in SPR experiments, solubility is not a factor in 
ZCL278's ability to bind Cdc42 immobilized on the CM5 chip. 
 
D5.  ZCL278 inhibits Cdc42-mediated microspike formation  
 We assessed the 30 selected ZCL compounds for their ability to inhibit Cdc42-mediated 
microspike/filopodia formation in serum-starved Swiss 3T3 fibroblasts. Actin-based 
microspikes/filopodia are characteristic of Cdc42 activity in cultured fibroblastic cells (Kozma et 
al., 1995; Nobes and Hall, 1995).  As shown in Fig. 3.4A, DMSO-treated (control) cells have 
few microspikes along its perimeter (arrows) as well as the characteristic presence of RhoA-
mediated stress fibers (asterisk).  When arrested fibroblasts were briefly stimulated with 1 
unit/mL of a commercial Cdc42 activator (CN02, Cytoskeleton, Inc. Denver, CO), a dramatic 
increase in microspike number and decrease in stress fibers occurred (Fig. 3.4A, Activator). 
Compound ZCL278 was applied at 50 μM for either 15 minutes, or for 1 hour and then 
stimulated with the Cdc42 activator for 2 minute.  After 15 minute incubation, the cell periphery 
of ZCL278-treated cells resembles control cells with few microspikes (Fig. 3.4A, ZCL278).  
Following 1 hour of ZCL278 treatment and Cdc42 stimulation, there is obvious inhibition of 
microspike formation (Fig. 3.4A, Activator+ZCL278) as compared to cells treated with only the 
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activator (Fig. 3.4A, Activator). ZCL197 and ZCL279, two other compounds with favorable 
predicted binding to Cdc42, either failed to inhibit microspike formation (Fig. 3.4A, 
Activator+ZCL197), or induced branched cellular processes resembling RhoA suppression (Fig. 
3.4A, Activator+ZCL279). Therefore, ZCL278, but not ZCL197 or ZCL279, inhibits Cdc42-
mediated microspike formation. Although ZCL278 displayed the most striking inhibitory effects 
on microspike formation among the 30 compounds tested, 4 other promising compounds 
identified from the virtual screening showed similar properties. The chemical structures of these 
4 compounds, along with 6 other ZCL compounds, are described in Fig. 3.5.  
In our in silica screening model, the Cdc42-ITSN interaction interface defines a binding 
pocket of 16 residues in Cdc42. We aligned the sequences of Cdc42 (P60953, from GenBank, 
http://www.uniprot.org/uniprot/), Rac1 (P63000) and RhoA (P61586) (Fig. 3.6). One of the 16 
residues is different between Cdc42 and Rac1 (Phe56 (Cdc42)/Trp56 (Rac1)), while 3 residues 
are different between Cdc42 and RhoA (Asp38 (Cdc42)/Glu40 (RhoA), Phe56/Trp58, 
Gln74/Asp76). The determinant for the selectivity of these Rho GTPases toward their GEFs is 
Phe56 (Cdc42)/Trp56 (Rac1)/Trp58 (RhoA). We thus further performed studies to compare 
ZCL278 with Y-27632, a RhoA/Rho kinase inhibitor (Wennerber and Der, 2004; Fritz and 
Kaina, 2006), under the condition that RhoA is activated (Fig 3.4B, left). We also performed 
studies to compare ZCL278 with NSC23766, a Rac1 selective inhibitor (Kwon et al., 2000), 
under the condition that Rac1 is activated (Fig. 3.4B, right). These results demonstrated that 
ZCL278 inhibits Cdc42-mediated (Fig. 3.4A), but not RhoA- or Rac1-mediated phenotypes (Fig. 
3.4B). 
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D6.  ZCL278 inhibits Cdc42 activity  
 Since ZCL278 showed the direct binding to Cdc42 and displayed most inhibitory effects 
in a morphological assay of Cdc42 function, we analyzed its activity at a biochemical level.  
First, Cdc42 activation was investigated in human metastatic prostate cancer PC-3 cells that were 
treated with the Cdc42 activator or 50 μM ZCL278 for 5, 10, and 15 minutes. Serine 71 
phosphorylation is known to negatively regulate Rac/Cdc42 activity (Uehata et al., 1997), thus 
an increase in phospho-Rac/Cdc42 expression is indicative of a decrease in active (GTP-bound) 
Rac/Cdc42.  As depicted in Fig. 3.7A, activation of Cdc42 shows an expected decrease in 
phospho-Rac/Cdc42.  However, the application of ZCL278 resulted in a time-dependent increase 
in Rac/Cdc42 phosphorylation. 
Wiskott-Aldrich syndrome Protein (WASP) is a downstream effector of Cdc42 activation 
(Ridley, 2006).  Tyrosine phosphorylation of WASP is linked to rapid Cdc42 degradation 
following its activation (Suzuki et al., 1999; Gao et al., 2004).  As shown in Fig. 3.7A, the Cdc42 
activator leads to a decreased expression of phospho-WASP by 15 minutes while ZCL278 does 
not suppress phospho-WASP activity.  Thus, ZCL278 inhibits Rac/Cdc42 phosphorylation in a 
time-dependent manner and maintains tyrosine phosphorylation of WASP. 
Serine 71 phosphorylation can occur on both Rac and Cdc42. To directly assess specific 
Cdc42 activation and inactivation, we utilized a G-LISA®, an ELISA-based assay that allows a 
quantitative determination of the levels of GTP-bound (active) Cdc42 in cellular lysates.  Serum-
starved Swiss 3T3 fibroblasts were incubated for 1 hour with 50 μM ZCL278 or 10 μM 
NSC23766 (Rac inhibitor), followed by 2 minutes of stimulation with 1 unit/mL Cdc42 
activator. This analysis revealed a significant increase (70%) in GTP-bound Cdc42 in cells 
treated with the activator as compared to control (untreated) cells (Fig. 3.7B). Cells treated with 
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ZCL278 showed a dramatic (nearly 80%) decrease in GTP-Cdc42 content as compared with 
cells treated solely with the activator.  Finally, we analyzed the ability of NSC23766 to cross-
inhibit Cdc42 activation.  NSC23766 was developed in a similar manner as ZCL278; however, it 
is specific to Rac and should therefore act as an additional negative control in this assay (Kwon 
et al., 2000).  As expected, NSC23766 does not reduce GTP-Cdc42 content (Fig. 3.7B).  These 
data establish that ZCL278 inhibits Cdc42 in two different cell types. 
 
D7.  ZCL278, but not NSC23766, disrupts the peri-nuclear distribution of active Cdc42  
 To confirm the ability of ZCL278 to selectively inhibit Cdc42 activation at the cellular 
level, serum starved Swiss 3T3 cells were treated with either 50 μM ZCL278 or 10 μM 
NSC23766 and were subsequently stimulated for 2 minutes with the Cdc42 activator (Fig. 3.8).  
Cells were probed with a mouse monoclonal antibody against active (GTP-bound) Cdc42 (Fig. 
3.8A, represented in psuedocolor setting (MetaMorph™ 4.6 imaging software systems 
(Molecular Devices, Sunnyvale, CA) for clarity).  Nuclei were visualized in dark blue by 
Hoechst staining.  Control fibroblasts showed an organized peri-nuclear distribution of active 
Cdc42 (Fig. 3.8A).  Cdc42 activation increased this distribution in the peri-nuclear region as well 
as in the nucleus (Fig. 3.8A), consistent with the established roles of Cdc42 in Golgi-based 
protein trafficking (Torres and Rosen, 2003).   ZCL278 clearly disrupted this organization and 
reduced immunoreactivity of anti-active Cdc42 while NSC23766 did not have the same effects 
(see also the quantification of the percentage of cells showing organized perinuclear distribution 
in Fig. 3.8B). Additionally, application of the Cdc42 activator, ZCL278 or NSC23766 did not 
elicit significant changes in phospho-RhoA immunoreactivity (Fig. 3.8C). These results again 
indicate that ZCL278 selectively inhibits Cdc42. 
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D8.  ZCL278, but not NSC23766, disrupts GM130 docked Golgi organization  
 To determine whether the ZCL278-induced disruption of peri-nuclear distribution of 
active Cdc42 reflected its effects on Golgi organization, we examined GM130, a peripheral 
cytoplasmic protein that is tightly bound to Golgi membranes and helps to maintain cis-Golgi 
structures (Torres and Rosen, 2006; Harris and Tepass, 2010). Control, serum-starved Swiss 3T3 
cells showed well-developed stress fibers (Fig. 3.9, red) and GM130 immunoreactivity 
polarizing to one side of the nucleus (Fig. 3.9, green-asterisk). Treatment with the Cdc42 
activator led to increased microspikes, as expected (Fig 3.9, red-arrows and insert, arrowheads), 
and intense peri-nuclear GM130 immuroreactivity (Fig. 3.9, green-asterisk).  As depicted in Fig. 
3.9 (also see Fig. 3.4A), ZCL278-treated cells show not only fewer microspikes but also a clear 
reduction of GM130 immunoreactivity as well as its dissipation to both sides of the nucleus (Fig. 
3.9, green-asterisk). Rac inhibitor NSC23766 did not significantly alter GM130 expression or 
distribution (Fig. 3.9-green-asterisk). These results not only further confirm ZCL278 as a 
specific Cdc42 inhibitor, but also demonstrate the importance of Cdc42 in Golgi organization 
and protein trafficking. 
 
D9.  ZCL278 impedes wound healing without disruption of cell viability 
  Filopodia are dynamic structures that aid cells in pathfinding and migration (Erickson et 
al., 1996; Nakamura et al., 1995), and are largely controlled by Cdc42 activity (Gupton and 
Gertler, 2007). Using a metastatic line of human prostate cancer cells (PC-3), we employed a 
wound healing assay in order to elucidate the effects of ZCL278 on cellular migration.  
Quiescent PC-3 cells were wounded with a sterile pipette tip and treated with or without the 
Cdc42 activator, ZCL278, or the Rac inhibitor NSC23766 for 24 hours.  As shown in Figure 
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3.10A and quantified in Fig. 3.10B, Cdc42 activation resulted in a significant increase (59%) in 
wound healing ability in comparison to controls (41%). Application of 50 μM and 5 μM ZCL278 
inhibited PC-3 migration into the wound area.  However, wound closure was less pronounced at 
50 μM (8%) than 5 μM (30%) concentrations. Cellular migration was also significantly reduced 
with NSC23766 treatment. This result is to be expected since Rac regulates the formation of 
lamellipodia, which are well-described motile structures (Nemethova, 2008).  These data, which 
are in agreement with our biochemical analysis, suggests that ZCL278 is not only a selective 
inhibitor of Cdc42 activation but also a potent suppressor of Cdc42-dependent cell motility. 
 In order to ensure that decreases in cellular migration seen with ZCL278 treatment was 
due to Cdc42 inhibition (or Rac inhibition when treated with NSC23766) rather than cell death, 
we tested cell viability using the trypan blue dye exclusion assay.  PC-3 cells were arrested in G0, 
and then 50 μM ZCL278 or 10 μM NSC23766 was applied for 24 hours.  Fig. 3.10C 
demonstrates that there was no difference in viability between treated and non-treated (control) 
cells.  Therefore, we conclude that the differences seen in migratory ability are due to ZCL278-
mediated Cdc42 inhibition or NSC23766-mediated Rac inhibition and not cell death. 
 
D10.  ZCL278 inhibits neuronal branching and growth cone dynamics   
 Cdc42 plays a crucial role in the establishment of neuronal morphogenesis (Garvalov et 
al., 2007). Cdc42’s absence in neurons resulted in a significantly reduced number of neurites and 
severely disrupted filopodia function (Yang et al., 2006). Therefore, we tested the ability of 
ZCL278 to inhibit neuronal branching in primary neonatal cortical neurons.   
At 5 days cultured in vitro, cortical neurons extended neurites with multiple branches 
(Fig. 3.11A, Control). 50 μM of ZCL278 was applied for 5 and 10 minutes, while DMSO-treated 
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neurons were maintained as negative controls. As demonstrated in Fig. 3.11A, neuronal 
branching was suppressed in ZCL278-treated neurons over the time course in comparison to the 
highly branched neurites of control cells.  Quantitative measurements found the branch number 
to be significantly reduced in ZCL278 treated neurons (Fig. 3.11B).  
Cdc42 is also widely known to control filopodia and microspikes at the leading edge of 
migrating growth cones (Ridley and Hall, 1992). Time-lapse video light microscopy shows a 
control cortical neuron with multiple microspikes or filopodia extended from the growth cone 
(Fig. 3.11C). However, ZCL278 treatments resulted in rapid retraction of filopodia within 4 
minutes (Fig. 3.11C). Thus, these studies further support ZCL278 as an effective small-molecule 
inhibitor of Cdc42-mediated neuronal branching and growth cone motility.  
 
E.  Discussion 
Signaling through the Rho GTPase pathway allows cells to accomplish a myriad of 
cellular tasks including membrane trafficking, cell cycle control, and the regulation of 
cytoskeletal organization, which strongly influence cell morphology, motility, and cell fate 
(Brown et al., 2000; Govek et al., 2005, Hall, 1998). Currently, many pathological conditions 
have been attributed to Rho GTPase dysfunction or de-regulation, making them prime candidates 
for pharmaceutical intervention (Jaffe and Hall, 2005; Lu et al., 2009).   
The available small molecule modulators of Rho GTPases have facilitated the 
exploitation of this important family of proteins. Notably, fasudil and Y-27632 are well-
established and potent inhibitors of Rho kinase/p160
ROCK
, one of the main downstream effectors 
of RhoA (Fritz and Kaina, 2006; Wennerberg and Der, 2005). Recent development of NSC23766 
targeting Rac1-GEF interaction filled a gap in studies on Rac as a selective Rac1 inhibitor 
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(Kwon et al., 2000). However, there are few choices for effective small molecule inhibitors 
selective for Cdc42. Secramine, an analog of natural product galanthamine, was discovered 
recently by its ability to inhibit Cdc42-dependent Golgi to plasma membrane transport through 
RhoGDI1 (Pelish et al., 2006). Unlike the widely used Y-27632 (1903 publications) or 
NSC23766 (115 publications), secramine availability is very limited and few studies can be 
found in literature today (9 publications). Cdc42 de-regulation has been linked to various aspects 
of tumorigenesis, including transformation and metastasis (Boettner and Van Aelst, 2002; 
Stengel and Zheng, 2011).  Additionally, neuronal development and maintenance relies heavily 
on appropriate Cdc42 activity (Auer et al., 2011). Given the urgent need to discover an effective 
tool to study Cdc42, we undertook the similar strategy in the discovery of NSC23766 and 
identified potential Cdc42 inhibitors by screening over 197,000 small molecules coupled with 
biochemical and cell-based verifications. Among the 30 potential leads that interfered with 
fibroblastic cell morphology related to Cdc42 function, ZCL278 emerged as the most effective 
and selective compound. ZCL278 synthesis involves few steps and is cell-permeable, therefore 
quite amenable for further exploitation as a pharmaceutical tool. In this study, we provide 
evidence for the characterization of the first effective Cdc42 small molecule inhibitor, which 
specifically and directly targets the binding site of its GEF, ITSN.  This is yet another example of 
identification of small molecule modulator of biologically significant signaling pathways based 
on computer-assisted screening (Kwon et al., 2000; Massa et al., 2002).  
Several studies have previously demonstrated the importance of Cdc42 activation for 
epithelial-to-mesenchymal transition (EMT) and resultant cellular movement that is necessary 
for cancer cell invasion (Chen et al., 2010; Johnson et al., 2010).  Using a wound healing assay, 
we showed that treatment with a Cdc42 activator is capable of enhancing wound closure in 
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comparison to non-treated cells, bolstering evidence for Cdc42’s ability to enhance the 
metastatic activity of cancer cells.  Significantly, ZCL278 was able to inhibit the migratory 
ability of PC-3 cells in a concentration dependent manner. Furthermore, ZCL278 is not cytotoxic 
to cells, therefore cell death is not the reason for the significant reduction in migration.  Our 
studies raised an exciting possibility that ZCL278 can be further investigated for its ability to 
inhibit cancer cell invasion and metastasis in vivo.   
Our studies on primary cortical neurons also support the role of Cdc42 in neuronal 
development. As elegantly demonstrated by Garvalov et al. (2007), brain and neuronal 
development are severely disrupted in Cdc42 deficient mice (Garvalov et al., 2007).  These mice 
exhibit a range of brain abnormalities including reduced axonal tracts, while neurons displayed a 
decrease in filopodial dynamics, increased growth cone size, and suppressed axon generation.  
Application of Cdc42 inhibitor ZCL278 to primary neurons reduced the number of branches 
formed and impeded growth cone dynamics.  This is consistent with the notion that axon and 
dendrite motility is largely an actin-based process that is highly regulated by Cdc42 (Watabe-
Uchida et al., 2006).  Thus, ZCL278 is the first small molecule inhibitor of Cdc42-ITSN 
interaction and provides a powerful tool for further elucidation of Cdc42 function in human 
diseases including cancer and neurologic diseases. 
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Figure 3.1  Identification of ZCL compounds targeting Cdc42-ITSN interaction.      
 (A) Docked posture of ZCL278 in the Cdc42 binding pocket: protein is shown as gray surface; 
ligand is depicted by green sticks. (B) Proposed interactions between ZCL278 and Cdc42 
residues: ZCL278 is in green; Cdc42 is shown as gray cartoon; residues of Cdc42 are in gray 
sticks; hydrogen bonds are represented as orange dash lines. (C). Superposition of GMP PCP 
(from Protein Data Bank: 2QRZ) and the docked Cdc42-ZCL278 complex. Cdc42: gray cartoon; 
ZCL278: green sticks; GMP-PCP: cyan sticks. (D). Synthesis of ZCL278. Reagents and 
conditions: (a) Ethyl 2-bromoacetate, K2CO3 , DMF, 70 °C; (b) NaOH, dioxane/H2O; (c) SOCl2, 
DMF, reflux; (d) NaSCN, acetone, 0 °C to room temperature; (e) 4-amino-N-(4,6- 
dimethylpyrimidin-2-yl) benzenesulfonamide, 0 °C to room temperature. Note: GMP-PCP is 
GTP analog guanylyl beta, gamma-methylene diphosphonate (i.e. the presumed signaling-active 
state).  
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Figure 3.2  The competition between ZCL278 and GTP for Cdc42 interactions and 
the effect on GTPase activity.  
(A) Increasing GTP concentration competes with ZCL278 preloaded on Cdc42 and increases 
GTP hydrolysis by purified recombinant Cdc42 protein in vitro as depicted by increasing levels 
of inorganic phosphate. *: p < 0.01; **: p < 0.00002. (B) Increasing ZCL278 addition competes 
with preloaded GTP on Cdc42 and reduces GTP hydrolysis by purified recombinant Cdc42 
protein in vitro as demonstrated by the decreased levels of inorganic phosphate. *: p <0.0006. 
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Figure 3.3  Determination of ZCL278 and Cdc42 binding. 
(A). Fluorescence titration of Cdc42 with compound ZCL278. Fluorescence emission at 350 nm 
was monitored. Kd = 6.4μM. (B). Surface plasmon resonance measurement of Cdc42-ZCL278 
interaction. (C). Surface plasmon resonance determined a Kd = 11.4 μM for Cdc42-ZCL278 
affinity. 
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Figure 3.4  ZCL278 inhibits Cdc42-mediated microspike formation.  
(A) ZCL278, but not ZCL197or ZCL279, inhibits Cdc42-mediated microspike formation. Swiss 
3T3 cells were treated with or without Cdc42 ligands identified by the high-throughput in silico 
screening. While DMSO was used as a control, 1 unit/mL Cdc42 Activator was applied to 
stimulate Cdc42.  50 μM ZCL278, ZCL197, or ZCL279 was applied for either 15 minutes 
without activation of Cdc42, or for 1 hour and then stimulated with the Cdc42 activator for 2 
minutes. Following treatments, cells were fixed and stained with rhodamine phalloidin to label 
filamentous actin. Arrows point to the cell periphery where microspikes may be seen.  Insets 
show high magnification of microspikes (yellow arrowheads). Asterisks indicate the subcellular 
locations that normally show stress fiber distribution. Bar: 5 μm (B). ZCL278 does not induce 
RhoA inhibition mediated branching of cellular processes nor suppresses Rac1-mediated 
lamellipodia formation. Asterisks indicate stress fiber distribution while arrows point to 
lamellipodia and white arrowheads point to branched cellular processes. Bar: 5 μM.  
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Figure 3.5  Examples of ZCL series compounds identified from the in silica screening as 
targeting Cdc42-ITSN interaction.  
Most of these ZCL compounds showing favorable Cdc42-ITSN interaction display activities to 
suppress fibroblastic microspike formation with the exception of ZCL-279, which induced 
branched cellular processes resembling RhoA suppression and ZCL197, which did not suppress 
microspike formation. 
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Figure 3.6   Alignment of the sequences of Cdc42, Rac1, and RhoA highlighting the 
residues identified as part of the GTPase-ZCL compound binding pocket.  
We aligned the sequences of Cdc42 (P60953, from GenBank, http://www.uniprot.org/uniprot/), 
Rac1 (P63000) and RhoA (P61586). The 16 interacting Cdc42 residues, Thr35, Val36, Phe37, 
Asp38, Asn39, Phe56, Asp57, Ala59, Gly60, Gln61, Tyr64, Leu67, Leu70, Ser71, Pro73, and 
Gln74, are highlighted in the alignment.  One of these 16 residues is different between Cdc42 
and Rac1 (Phe56 (Cdc42)/Trp56 (Rac1)), while 3 residues are different between Cdc42 and 
RhoA (Asp38 (Cdc42)/Glu40 (RhoA), Phe56/Trp58, Gln74/Asp76). The determinant for the 
selectivity of these Rho GTPases toward their GEFs is Phe56 (Cdc42)/Trp56 (Rac1)/ Trp58 
(RhoA) [22] which is also included in our defined binding pocket of Cdc42. Thus, this makes it 
feasible to identify selective inhibitors of Cdc42. 
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Figure 3.7  ZCL278 inhibits Cdc42 expression and activity. 
(A) ZCL278 inhibits endogenous Rac/Cdc42 activities. Serum-starved PC-3 cells were treated 
with either the Cdc42 activator at 1 unit/mL or 50 μM ZCL278 for the indicated time points. Cell 
lysates were subjected to Western blot analysis utilizing the following antibodies: phospho 
Rac1/cdc42 (upper), phospho-WASP (middle), and GAPDH (lower). (B) ZCL278, but not 
NSC23766, inhibits stimulated Cdc42 activity. Serum-starved Swiss 3T3 cells were incubated 
for 1 hour with either 50 μM ZCL278 or 10 μM NSC23766 and then stimulated for 2 minutes 
with a Cdc42 activator at 1 unit/mL. Cell lysates were then subjected to a colorimetric G-LISA® 
assay to measure GTP-bound Cdc42. A constitutively active Cdc42 was used as positive control. 
Negative controls included buffer only controls as well as untreated cellular lysates. Results 
shown are averaged from three independent experiments (n= 3/ group) ± S.E. (**, p< 0.01, *, 
p<0.05). 
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Figure 3.8  Immunofluorescence light microscopy of active Cdc42 and phosphorylated RhoA.  
Serum starved Swiss 3T3 cells were treated with either DMSO as control, a Cdc42 activator, 50 
μM ZCL278 or 10 μM NSC23766. Treatments with ZCL278 or NSC23766 were followed by 
stimulation for 2 minutes with a Cdc42 activator at 1 unit/mL. In order to determine if ZCL278 
selectively inhibits Cdc42 but not RhoA activity, cells were probed with an active Cdc42 (A, and 
B) or phosphorylated RhoA (C) antibodies. Arrows: peri-nuclear organization of active Cdc42 
possibly corresponding to the Golgi- ER network.  In order to more clearly visualize staining 
intensity, active Cdc42 immunostaining is represented using the pseudocolor setting of the 
MetaMorph™ 4.6 imaging software systems (Molecular Devices, Sunnyvale, CA).  Light blue 
indicates areas of higher intensity, whereas purple indicates areas of lower active Cdc42 
intensity. Nuclei were visualized in dark blue by Hoechst staining. Bar: 15 μm. (B) Active Cdc42 
associated with organized perinuclear Golgi-ER network was quantified. Organized Golgi-ER 
was quantified in five randomly selected regions of cells in each treatment group using the 
pseudocolor setting (*, p< 0.05). (C) Pixel intensity of phospho-RhoA in cells after treatments 
with Activator, ZCL278, or NSC23766 was quantified. Results reflect the averaged intensity 
generated at five random points in five independent cells (n= 5/ group) ± S.E. (*, p< 0.03). 
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Figure 3.9  ZCL278 disrupts GM130 docked Golgi organization.   
Serum-starved Swiss 3T3 cells were treated with DMSO as control, a Cdc42 activator, ZCL278, 
or NSC23766. Following the treatment, cells were stained by rhodamine phalloidin (Red), anti-
GM130 (green), and Hoechst (blue). Arrows point to the cell edges where microspikes can be 
seen in phalloidin-stained cells (red). Insert shows the high magnification of the cells treated 
with the Cdc42 activator, where arrowheads point to microspikes. Asterisks in (green) point to 
the Golgi structure immunolabeled by anti-GM130. Cdc42 activation led to increased 
microspikes, as expected (Activator: red-arrows and insert: arrowheads), and intense peri-nuclear 
GM130 immuroreactivity (Activator: green-asterisk). Cells treated with ZCL278 showed fewer 
microspikes (ZCL278: red). GM130 immunoreactivity is clearly reduced and distributed to both 
sides of the nucleus (ZCL278: green-asterisk). Rac inhibitor NSC23766 did not significantly 
alter microspike formation (NSC23766: red-arrows) and GM130 expression or distribution 
(NSC23766: green-asterisk). Bar: 10 μm. 
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Figure 3.10  ZCL278 impedes cellular migration without disruption of cell viability. 
(A) Serum starved PC-3 cells were grown to confluent monolayers, wounded using a sterile 
pipette tip, and incubated for 24 hours with a Cdc42 activator at 1 unit/mL, 50 μM ZCL278, 5 
μM ZCL278, or 10 μM NSC23766. The distance of migration was then analyzed by phase 
contrast microscopy and MetaMorph™ 4.6 imaging software systems (Molecular Devices, 
Sunnyvale, CA). Black lines indicate the leading edge of the wound. (B) Wound healing was 
quantified at 0 and 24 hours by measuring the shortest distance between the edges of the scratch. 
Columns represent the wound healing as a percentage of the original wound distance.  Results 
shown are averaged from three independent experiments (n= 3/ group) ± S.E. (**, p< 0.01, *, p< 
0.05). (C) Serum-starved PC-3 cells were incubated for 24 hours with 50 uM ZCL278 or 10 uM 
NSC23766. Cell viability was determined using a Countess Automated Cell Counter (Invitrogen) 
combined with trypan blue dye staining of cells. 
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Figure 3.11  ZCL278 inhibits neuronal branching and growth cone motility. 
Primary cortical neurons from postnatal day one mouse pups were cultured on poly-L-lysine 
coated coverslips. (A) Neurons were treated at 5 days in vitro with either DMSO (control) or 50 
μM of ZCL278 for 5 and 10 minutes. Neurons were then fixed and actin based structures were 
identified with rhodamine phalloidin labeling. While control neurons showed multiple branches 
(arrows), ZCL278 treatment reduced the branch numbers (arrowheads). (B) The number of 
branches was counted on neurons treated with ZCL278. Results shown are averaged from 3 
independent experiments (n= 3/ group) ± S.E. (*, p< 0.01). (C) Time-lapse imaging of cortical 
neuronal growth cone motility. While the control neuron maintains multiple microspikes or 
filapodia, ZCL278 treatment led to rapid retraction of microspikes or filopodia. Bar: 1 μm. 
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CHAPTER IV: Conclusions and General Discussion 
 It is abundantly clear through a variety of clinical and experimental studies that Rho 
proteins are critical regulators in many cellular functions which lead to their varied and important 
roles in pathological conditions ranging from cardiovascular and neurological dysfunction to 
cancer initiation and progression.  Additionally, there are multiple lines of evidence supporting 
Rho pathway intervention as a viable treatment for several human disease conditions including 
cerebral vasospasm (Loirand et al., 2006; Shibuya et al., 1992) and pulmonary hypertension 
(Kishi et al., 2005). RhoA inhibitor LM11A-31 is currently in phase I human clinical trials as an 
Alzheimer's disease treatment, after marked success in mice (Knowles et al., 2013; Tep et al., 
2013; Yang et al., 2008). For these reasons, Rho proteins are very attractive targets for drug 
development and therapeutic intervention (Lu et al., 2009).  In the current study, we aim not only 
to understand the role of RhoA in chemotherapy induced neurotoxicity but to fill a substantial 
gap in Rho protein signaling by identifying and characterizing novel small molecules that 
specifically target Cdc42 activation.   
 In Chapter II, we confirmed that cisplatin induced RhoA activation in our in vivo CIPN 
model.  In addition, this increase in RhoA activity was correlated with decreased peripheral 
nerve sensitivity and increased neuronal damage.  Furthermore, application of upstream RhoA 
inhibitor LM11A-31 alleviated cisplatin-induced rise in RhoA activity and neurodegeneration.  
Importantly, our work expands on previous data supporting RhoA inhibition in CIPN recovery 
(James et al., 2010) and demonstrates that RhoA pathway suppression could be used in 
conjunction with clinically relevant doses of cisplatin chemotherapy to prevent CIPN 
development.  This study, therefore, could have important clinical implications for patients 
undergoing chemotherapy.  LM11A-31 is well tolerated in mice and capable of oral uptake and if 
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clinical trials are successful in human patients, this compound could be easily be transitioned 
clinically to an adjuvant therapy to cisplatin. 
 However, because the animals in our study are normal, healthy, young mice our results 
might be slightly skewed from what would be seen in a more clinically relevant tumor-bearing 
mouse model.  Therefore, it will be very important to confirm the present results in a modified 
CIPN model. Currently our cisplatin doses are not only clinically relevant to human patients but 
have also been shown in mouse models of lung cancer (Oliver et al., 2010) and breast cancer 
(Shafee et al., 2008)  to be effective and tolerable.  Additionally, due to RhoA's known relevance 
to several types of cancer, application of Rho inhibitors may have a compound effect of 
decreasing tumor progression and preventing CIPN, which would make Rho suppression an even 
more valuable clinical target.  In fact, studies support that pharmacological inhibition of Rho-
kinase with Y-27632 could not only reduce melanoma tumor volumes (Routhier et al., 2010) but 
also decrease metastasis of breast cancer cells in C57/BL6 mouse models (Liu et al., 2009).  
Furthermore,  recent work has indicated that Y-27632 and fasudil could also enhance the 
cytotoxic effects of cisplatin in in vitro models of ovarian cancer (Ohta et al., 2012). 
 Further study is needed to confirm the mechanism of cisplatin-induced neurodegeneration 
in the peripheral nerve.  Although our study confirmed the involvement of the RhoA signaling 
pathway and implicated SHP2 phosphatase in the neurodegenerative mechanism, we still lack a 
clear understanding of cisplatin's direct target.  Studies have suggested a preferential 
accumulation of cisplatin within the dorsal root ganglion (DRG) thereby increasing the 
likelihood of apoptosis (McDonald et al., 2005).  However, this does not adequately explain the 
differences seen clinically from one patient to another, where their ability to recover varies from 
partial to full or they sustain permanent debilitation.  It is more likely that cisplatin may also 
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target the nerve directly, due to its lack of protection by the blood brain barrier, thereby allowing 
cisplatin to affect the Schwann cell population and underlying axon with little interference.  
Additionally, it is unclear whether cisplatin may preferentially target smaller, more distal nerve 
fibers and endings, as opposed to larger more proximal nerves.  Our studies suggest that cisplatin 
impacts nerve fiber morphology, especially in the level of myelination, which may explain the 
overall reduction in fiber size and subsequent reductions in axonal area.  Interestingly,  RhoA is 
known to be modulated by myelin-associated inhibitors Nogo (Chen et al., 2000b), myelin-
associated glycoprotein (MAG; McKerracher et al., 1994) and oligodendrocyte-myelin 
glycoprotein (OMgp; Wang et al., 2002) which are well established in inflammatory-induced 
neuronal injuries. 
 Also of importance is the ability to understand how other Rho proteins (Rac1 and Cdc42) 
possibly contribute to CIPN generation.  Many studies confirm signaling relationships between 
Rho proteins whereby they can antagonize or support each other.  Although we have access to 
specific Rac1 inhibitor NSC23766, we were severely lacking small molecules that could be 
utilized to inhibit Cdc42 and be applied to our CIPN model.  Therefore, in Chapter III we sought 
to develop and characterize small molecules that had the potential to fit into the GEF binding 
pocket of Cdc42 and specifically inhibit its activation.  Our work identified compound ZCL278, 
which was able to bind and inhibit Cdc42-mediated functions such as microspike formation, 
Golgi organization, neuronal branching and cell motility.  Importantly, ZCL278 was found to be 
cell permeable and quite easy to synthesize, making it an amenable option for use as a 
pharmaceutical lead.   Moreover, ZCL278 did not alter Rac1 or RhoA-mediated activation or 
activity.  
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 Identification of small molecule inhibitors of protein-protein interactions is becoming 
increasingly important due to the key roles they can play in many biological processes and their 
potential for therapeutic intervention.  Small molecules can be highly specific for their molecular 
targets, and are thus of high interest to scientific investigators, pharmaceutical companies, and 
clinical researchers.  Identification of ZCL278 has opened an important door to further 
understanding of Cdc42 signaling pathways. It will help determine how Cdc42 cooperates or 
antagonizes other Rho proteins, and the roles it plays in biological processes underlying human 
disease states.  Additionally, ZCL278 identification will hopefully spur further screenings to 
identify more specific activators and inhibitors of Cdc42 as well as other Rho family members. 
 The next steps in order to utilize ZCL278 in our CIPN mouse model will be to elucidate 
its effects in vivo and determine proper dosage.  First, determination of appropriate routes of in 
vivo administration, including method and vehicle are needed.  Next, we will not only have to 
determine tolerability of the compound, but also ascertain appropriate dosage regimens.  
Furthermore, toxicity of ZCL278 will also have to be assessed by histological analysis of 
harvested tissue.  Once characterized and determined to be safe for in vivo use, we can then 
modify our CIPN protocol to include ZCL278-mediated Cdc42 inhibition and investigate 
possible cross regulation of Cdc42 and RhoA. 
 Due to the described hierarchical relationships between Rho proteins (Nobes and Hall, 
1995) it would be expected to see alteration in Rho proteins other than RhoA.  As a mutually 
inhibitory antagonistic relationship exists between RhoA and Cdc42 (Nobes and Hall, 1995) 
results might show decreased Cdc42 activation as a result of cisplatin treatment.  In fact, 
cisplatin and docetaxel were shown to suppress Cdc42 activity in a model of squamous cell 
carcinoma (Kogashiwa et al., 2010) and in a study of anticancer agents in human umbilical vein 
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endothelial cells (Bijman et al., 2006). In neurons, RhoA activation is also accompanied by the 
inhibition of Rac1 and Cdc42 (Yamaguchi et al., 2001; Wong et al., 2001).  However, to date, 
there are no studies that have investigated Rac1 and Cdc42 in CIPN nerves.  Understanding the 
totality of Rho GTPase function in cisplatin-induced neurotoxicity could allow us to more 
precisely target Rho-mediated neurodegenerative mechanisms that occur due to concurrent 
chemotherapeutic administration. 
 Overall, our studies further support Rho pathway intervention as a neuroprotective 
strategy that could be applied to a variety or human conditions, especially cisplatin-induced 
peripheral neuropathy.  We confirm RhoA activity is increased due to cisplatin and correlate it to 
the neurodegeneration incurred through treatment.  We established that LM11A-31, when co-
administered with cisplatin, could not only reduce RhoA activity, but protect peripheral nerves 
from the detrimental effects of cisplatin.  Additionally, by identification of ZCL278 we open a 
door for increased exploration of Cdc42 signaling in vitro that will hopefully one day allow us to 
assess Rho protein crosstalk in vivo in the CIPN mouse model.   ZCL278 has the potential to 
become a powerful molecular tool that can enhance continued Rho protein exploration and 
development of targeted therapies that support not only treatments for CIPN, but also cancer, 
cardiovascular disease, and other neurological problems. 
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